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Cancer cells are able to reprogram their metabolism in order to supply biosynthetic and 
bioenergetic demands of rapid proliferation. Glutamine is required by most cancers in 
significant quantities, as it serves as a major anabolic carbon and nitrogen source for 
synthesis of macromolecules, a source of high energy electrons for ATP production and the 
regulation of ROS homeostasis via glutamate through the synthesis of glutathione. The 
metabolism of glutamine in Medulloblastoma (MB) - the most common high grade 
childhood tumour – is largely unknown. 
Using publically available databases of MB gene expression, we observed that genes 
associated with glutamine metabolism were prognostic in MB patients. Furthermore, 
employing a combination of analytical approaches to study metabolism, we show the 
importance of glutamine catabolism in MB cell lines. Finally, we investigated the effect of 
pharmacological manipulation of glutamine metabolism and observed that inhibition of 
glutaminase 1 (GLS1) – the enzyme responsible for glutamate biosynthesis - can increase 
cisplatin and irradiation cytotoxicity. Taken together our data suggests that understanding 
glutamine metabolic pathways may generate prognostic bio-markers of survival and may 
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1.1 Introduction  
 
In 2016 Cancer research UK estimated that 5,187 deaths resulted from brain tumours in the 
UK, with a >10 year survival rate of little as 14% (CRUK, 2016). Furthermore, in this same 
year, the World Health Organisation (WHO) reported that brain and central nervous system 
tumours accounted for 8.8 million deaths worldwide (Louis et al., 2016).  Despite the 
significant research into these tumours, advancements in their treatment remain poor, with 
a clear need for novel effective therapies. One such approach with a hope to improve the 
diagnosis and treatment comes from the exploration of the tumour metabolome, which 
may be able to reveal phenotypic differences in relation to biological function. 
 
1.2 Introduction to Medulloblastoma 
 
Medulloblastoma (MB) is a rapid growing tumour of the cerebellum or medulla/brain stem.  
MBs are the most common malignant brain tumour observed in children, with extensive 
clinical and biological heterogeneity (Cavalli et al., 2017). The cell of origin for a number of 
different cancer types, including MB, is somewhat controversial. In MB, this is an ongoing 
debate, in which granule neurone precursors were speculated as being the cells of origin, 
due to the morphology and location of the arising tumours (Yang et al., 2008). However, 
stem cell markers have also been shown as being expressed on MB cells (Hemmati et al., 
2003), raising the argument that these tumours may arise from neural stem cells (NSCs). 
With the classification of MB into different subgroups (see below), it has been speculated 
that both cell types may equally be precursors, but result in a different subgroup of tumour 
(Robinson et al., 2012). Much of the controversy regarding MB cell of origin was due to 
difficulties in studying the initial phases of the neoplastic process (Huang et al., 2016). The 
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establishment of genetically engineered mouse (GEM) models led to an increased 
understanding of MB cellular origins, where it is now accepted that Shh-driven MBs are 
derived from the external germinal layer (EGL) (Schüller et al., 2008), Wnt MBs from the 
dorsal brainstem progenitors (Gibson et al., 2010) and Group 3 MBs from cerebellar stem 
cells (Fan and Eberhart, 2008), (Pei et al., 2012). Despite our increased knowledge of the 
neoplastic events leading to MB, the cell of origins in Group 4 MB remains elusive (Huang et 
al., 2016). 
 
1.3 The Who classification system for Medulloblastomas 
 
Over the past century, brain tumours have typically been classified based on their 
histological presentation (WHO 2007). However, the 2016 WHO classification of CNS 
tumours included molecular parameters alongside histology to characterise these tumours 
(Louis et al., 2016).  Specifically, the WHO classification of MBs adheres to the widely 
accepted 4 genetic subgroups: WNT activated, SHH-activated, group 3 and group 4 (Taylor 
et al., 2012). While the histological variants of MB (desmoplastic/nodular, extensive 
nodular, large cell and anaplastic) remain more relevant for clinical purposes (i.e. diagnosis, 
prognosis and treatment), clinical trials are starting to use genetic subgroup for stratification  
Both the genetic and histological groups are associated with different prognoses and 
treatment regimens, where it is expected that pathologists should integrate their diagnosis 















The WNT subgroup of MB has a peak incidence of around 10-12 years (Kool et al., 2008), 
and accounts for around 11% of MB tumours, making it the rarest subgroup. Despite this, 
Wnt tumours are the best studied of the subgroups, in part, due to its better clinical 
prognosis, with overall survivals reaching 90% (DeSouza et al., 2014). These tumours 
typically present as classic histology variants, although some large cell/anaplastic tumours 
are from this subgroup. Interestingly, this appears not to affect their more favourable 
prognosis compared to other subgroups (Louis et al., 2016).  
Mutations of the β-catenin encoding gene CTNNB1 are commonly observed in patients with 
WNT subgroup MB (Northcott et al., 2012), which leads to a disrupted Wingless (Wnt) 
system, a family of growth factor receptors involved in embryogenesis (Kool et al., 2008). In 
addition, germline mutations in APC (inhibitor of the Wnt pathway), which predispose 




individuals to Turcot syndrome, also brings a heightened risk of MB. Less frequent 
mutations that are observed in sporadic MB, include APC and AXIN1/2, all of which are 
crucial parts of the Wnt pathway. This therefore highlights the strong aetiological role for 
the canonical Wnt pathway activation in the formation of these tumours (Jenkins et al., 
2016).  Activation of Wnt signalling leads to accumulation of β-catenin in the nucleus, which 
binds to TCF-4/lef-1 and has a role in cell proliferation (Niehrs and Acebron, 2012), cell to 
cell adhesion (Niehrs, 2012) and in the breakdown of the extracellular matrix (Baryawno et 
al., 2010).  
1.3.2 SHH 
 
Another subgroup of MB attributed to altered signalling is the SHH subgroup, which account 
for around 28% of MBs, and have an intermediate prognosis. As the name suggests, these 
tumours are understood to be driven through oncogenic signalling through the sonic 
hedgehog pathway (DeSouza et al., 2014). Similarly to the WNT subgroup, SHH tumours can 
arise due to a germline mutation - in some cases mutations in PTCH, which lead to Gorlin 
syndrome, or mutations in SUFU, also predispose to MB (Smith et al., 2015). Sporadic SHH 
MBs are frequently associated with mutations in these same genes, but also of SMO (G 
protein-coupled receptor involved in shh signalling), in addition to genetic amplifications of 
GLI1 and GLI2 transcription factors (Bayly et al, 2012). The sonic hedgehog (Shh) pathway 
induces proliferation in neuronal precursor cells in the developing cerebellum and is 
therefore vital in regular cerebellar development (Álvarez-Buylla and Ihrie, 2014). More 
specifically, shh encourages development of the external germinal layer (EGL) within the 
upper rhombic lip (the origin of SHH tumours), directed by the Shh ligand which is usually 
secreted by Purkinje neurons (Ramsbottom and Pownall, 2016). All mutations associated 
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with this subgroup result in Shh signalling pathway over-activation. The binding of Shh 
ligand to its receptor PTCH1 overcomes SMO inhibition, allowing for the release of Gli 
transcription factors, which are normally bound to inhibitory protein complexes, typically 
SUFU (S. et al., 2016). Consequentially, this activation further results in an increased 
expression of Snail protein, and disruption of E-cadherin to decrease cell–cell adhesion (Li et 
al., 2007). Hedgehog activation has also been shown to strongly regulate angiogenesis and 
metastasis via Rho kinase-dependant mechanisms (Renault et al., 2010).  
Due to the progress made in molecular understanding of MB, it would be inappropriate to 
class SHH tumours as a single entity. The presence of TP53 mutations can dictate whether a 
SHH tumour has a moderate or a poor survival, with TP53 mutations leading to a high-risk 
subtype (Kool et al., 2014), (Schwalbe et al., 2017) and are responsible for a large proportion 
of treatment failures in SHH MBs (Ramaswamy et al., 2016). 
1.3.3 Group 3 (Grp3) 
 
Grp3 MBs are typically referred to as the C-MYC amplified subgroup and  make up about 
28% of all cases, a similar prevalence seen in SHH tumours (Cavalli et al., 2017) . These 
tumours have the worst prognosis across all of the subgroups and frequently metastasise 
(Robinson et al., 2012). Grp3 tumours are rarely observed in adults while their prevalence in 
infants and children is high, where they typically present histologically as classic or large 
cell/anaplastic (Taylor et al., 2012). It has been suggested that OTX2, a transcription factor 
that is strictly regulated during development and has been shown to upregulate the 




1.3.4 Group 4 (Grp4) 
 
Due to the unclear molecular pathogenesis of this subgroup, it is simply referred to as Grp4 
subtype, although there is an association with isochromosome 17q. Grp4 MBs are the most 
frequently occurring subtype, occurring in 34% of all cases, and usually occur in children, 
with a peak incidence at 10 years old (Taylor et al., 2012). Despite isochromosome 17q 
being observed in 26% of group 3 tumours, it is drastically more associated with Grp4 MB, 
being present in 66% of tumours (Desouza et al, 2014). Another noteworthy cytogenetic 
change within group 4 tumours is a common loss (80%) of Chromosome X in affected 
females (Northcott et al, 2012). These tumours present histologically as classic, though less 
often can present as large cell/anaplastic and despite common observations of metastatic 
disease, these tumours have an intermediate prognosis (Packer and Vezina, 2008) 
1.3.5. Beyond the conventional 4 groups of MB 
 
The inclusion of molecular phenotypes in the classification of MB has been a natural 
consequence of the recent increase in genetic research in MB tumours. More recently, 
genetic stratification into seven groups has been suggested (Figure 1.2). Schwalbe et al, 
stratified MB into seven molecular subgroups, of which the WNT subgroup was unaffected 
and each of the other recognised subgroups were split in two distinct groups. The SHH 
subgroup was divided into age-related subgroups corresponding to infant (<4-3 years) and 
childhood patients (≥4-3 years), while Grp3 and Grp4 MB were divided into low and high risk 





Figure 1.2 Summary of the seven primary childhood Medulloblastoma subgroups. 












However, in the same year Cavalli et al proposed 12 MB subtypes, in which the WNT 
tumours were split into two groups (Figure 1.3). Although the two WNT subtypes (WNT α 
and WNT β) were found to have similar prognoses. WNT α was found to affect mainly 
children and demonstrate monosomy 6, while WNT β occurred in older patients and were 
frequently diploid for chromosome 6. Interestingly, monosomy 6 had previously been 
defined as a defining feature of WNT MB (Zhao et al., 2016). However the more recent 
study suggested that WNT β patients could be misdiagnosed if this criterion were used 
alone (Cavalli et al., 2017). 
The same group identified four distinct groups of SHH MB; α, β, γ, and δ. The variant with 
the worst prognosis was found to be SHH α, affecting children between the ages of 3-16 
years and were typically enriched for GLI2 and MYCN amplifications. Somatic copy-number 
aberrations (CNAs) such as YAP1 amplifications, 9q, 10q and 17q loss were also observed in 
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this group. Furthermore, the SHH α group were highly enriched for TP53 mutations, where 
the TP53 mutation profile was only prognostic in the SHH α variant tumours. Furthermore, it 
was observed that infant SHH tumours were generally associated with SHH β and SHH γ with 
contrasting clinical consequences; SHH β tumours frequently metastasised and had a poorer 
overall survival compared to the SHH γ group, while SHH δ were associated with tumours in 
adults, contained activating mutations in the  TERT promoter and were more likely to have a 
better prognosis (Cavalli et al., 2017). 
Grp3 MB were also subdivided into three variants; α, β, and γ. The most surprising finding 
from this study was the observation that Grp 3γ have a poor prognosis independently 
of MYC amplification, identifying for the first time a group of high-risk Grp3 tumours, 
irrespective of MYC status (Cavalli et al., 2017). 
Grp 4 remained the most prevalent MB subgroup in this study, although was also split into 3 
variants (again, α, β, and γ). However, their frequency was found to be >40% of all MB 
compared to the previous finding of 34% (Louis et al., 2016). Grp 4α were observed to be 
enhanced for MYCN amplifications. Grp 4α and 4γ generally had 8p loss and 7q gain, while 
Grp 4β harboured SNCAIP (Synphilin-1) duplications and almost universal isochromosome 
17q. It had been previously proposed that Grp4 MBs were GFI1 and GFL1B activated 
(Northcott et al., 2014)- this report observed GFI activation only in Grp3 β.  
The genetic information regarding tumour classification is providing important steps 
forward in our understanding the tumourigenic processes in MB. However, it is not always 

















1.4 Clinical diagnosis 
 
The median interval from the onset of symptoms to eventual diagnosis in MB is around 8 
weeks, but can range from days to years (Gerber et al., 2012). Symptoms present as 
hydrocephalus and/or cerebellar dysfunction, comprising of increasing head circumference 
and vomiting in infants and cranial nerve palsy, ataxia, vomiting and headaches in older 
individuals (Gerber et al., 2014). Magnetic resonance imaging (MRI) is an invaluable tool in 
the diagnosis of MB, where tumours are visualised in the cerebellum, with regular fourth 
ventricle compression. Tumours typically obstruct draining of the cerebral spinal fluid (CSF), 
resulting in expansion of the lateral and third ventricles. Spinal MRI also contributes towards 
the diagnosis of metastatic MB. 
 
 
Figure 1.3 Graphical Summary of the 12 Medulloblastoma Subtypes. Figure taken 
from Cavalli et al., 2017. 
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1.5 Management of Medulloblastoma 
 
Recent developments in multimodal therapy such as chemotherapy, radiotherapy and 
surgery have shown promise, yet recurrence occurs in roughly 40% of these children, and 
approximately 30% succumb to their disease (Fossati, Ricardi and Orecchia, 2009). 
Furthermore, MB survivors have a considerably reduced quality of life due to treatment-
related side effects (Gerber et al., 2014). Whenever possible, surgery is favoured across all 
four subtypes, where maximal tumour resection is the foremost goal. Subsequent to 
surgery, older patients tend to receive varying doses (dependent on risk stratification) of 
multimodal chemotherapy in combination with craniospinal radiation. Stratification of 
patients into separate risk groups has been vital in controlling the de-escalation of 
treatment intensities, the purpose of which is to increase quality of life both directly after 
treatment and for those who are cured (Gerber et al., 2014).  
 
1.5.1. Molecular targeting of MB tumours 
 
Our increased understanding of the molecular alterations between MB subgroups has 
catalysed the development of targeted therapies, with the hope that these will reduce 
treatment associated side-effects in patients. Despite this, limited drugs targeted towards 
the Wnt pathway have been established in MB, which may be a result of their already 
excellent cure rate (Baryawno et al., 2010). Canthradin has previously been shown to inhibit 
phosphatase 2A (PP2A), which is needed in the stabilisation of β-catenin and functions 




Targeting SHH tumours on the other hand, has received considerably more attention. The 
vast majority of inhibitors developed have been targeted towards SMO, a vital component 
of the sonic pathway (Kieran, 2014), where a number of inhibitors have been assessed in 
clinical trials. However, despite initial responses, patients often relapse after treatment with 
SMO inhibitors, with secondary mutations in SMO likely driving resistance mechanisms 
(Yauch et al., 2009). The GLI family of transcription factors have presented as potential 
targets in patients with resistance to SMO inhibitors, though only arsenic trioxide (ATO) has 
progressed to clinical trials, despite other agents showing encouraging results in pre-clinical 
settings (Lin et al., 2016).  
 
In comparison to WNT and SHH MBs, the molecular targeting of Grp3 and Group4 MB has 
proven more difficult in recent years, possibly due to the scarce nature of recurrent 
mutations in these subgroups (DeSouza et al., 2014). Despite this, epigenetic manipulation 
has been a growing area of interest in these tumours, with chromatin modification genes 
shown to be involved in a number of patients. It was recently observed that class 1 and 2 
HDAC inhibition prompted significant responses in MYC amplified MB cell lines (Ecker et al., 
2015), although several trials have failed to reproduce these in vitro results in solid tumours 
(Vansteenkiste et al., 2008; Rathkopf et al., 2013), nor in MB patients. Some encouraging  
data regarding the targeting of metastatic Group3 tumours- in which high expression of 
PRUNE1 is observed, have been published (Ferrucci et al., 2018). Through use of a small 
molecule, AA7.1 (a pyrimido-pyrimidine derivative), they observed increased PRUNE1 
degradation resulting in a disrupted PRUNE1/TGF-β/OTX2/PTEN axis. They further 
demonstrated that in orthotropic xenograft mice, AA7.1 strongly impairs tumour growth 




Recent studies from Schwallebe and Cavalli have transformed our understanding of the 
genetic underpinning of MB, how this can inform subgrouping and permit the development 
and use of novel targeted therapies. The results are thus far encouraging for the 
management of MB, although primary and secondary drug resistance present significant 
clinical challenges and highlights the potential need for high quality second and third line 
therapies. Therefore, it is no surprise that many novel therapies are now targeting 
alternative mechanisms in cancer biology, including cancer metabolism. 
 
1.6 Introduction to cancer metabolism 
 
Metabolic alterations in tumours have been observed for nearly a century; one of the 
earliest seminal observations being that of aerobic glycolysis by Otto Warburg in the 1920’s 
(Warburg, 1925). However, cancer metabolism has received renewed attention over the 
past decade and is now considered a hallmark of cancer (Hanahan and Weinberg, 2011). 
This interest has been catalysed by innovation in analytical platforms such as mass 
spectrometry and nuclear magnetic resonance (NMR) spectroscopy, allowing for the 
expansion of our understanding of tumour-associated alterations in metabolism. Cancer 
cells, unlike the majority of normal, differentiated cells, typically consume glucose at higher 
rates, producing increased amounts of lactate - a  phenotype originally described by Otto 
Warburg as aerobic glycolysis, and more commonly referred to as the Warburg effect 
(Hanahan and Weinberg, 2011). Warburg proposed that the increased consumption of 
glucose was a direct consequence of compromised oxidative mitochondrial metabolism, and 
suggested that this was a common and unique component of all cancers (Warburg 1956). It 
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was later confirmed that this was not a feature unique to only cancer cells (Hedeskov, 
1968), and that not all tumours exhibited defects in oxidative metabolism (Wang, 
Marquardt and Foker, 1976; Brand, 1985). The transformed metabolism observed in 
tumours supports many of the other hallmarks outlined by Hanahan and Weinberg, 
including unrestrained growth. In order to support this increased rate of cell division, most 
tumours alter their metabolism in three main ways; enhanced generation of energy in the 
form of ATP, anabolic precursors capable of fulfilling macromolecule synthesis and anti-
oxidants to counteract increased oxidising effects brought about by both the tumour 
microenvironment and anti-tumour therapy. Two of the most significantly-utilised nutrients 
to support increased metabolism in tumours are glucose and glutamine. 
1.6.1 Glucose metabolism 
 
The enhanced rate of glycolysis observed in most tumours increases the production of ATP 
in the cytosol. Compared to the other process for ATP generation – oxidative 
phosphorylation – glycolytic ATP production is less efficient in terms of nutrient use, as it 
produces 2 moles of ATP per mole of glucose, compared to 38 moles of ATP per mole 
glucose by oxidative phosphorylation. However, the significant uptake and metabolism of 
glucose through glycolysis observed in tumours can compensate for this difference (Gillies, 
Robey and Gatenby, 2008; Bryant et al., 2014). This also conveys an added advantage to a 
tumour, as glycolysis can be sustained in the absence of oxygen (Pavlova and Thompson, 
2016). The increased uptake of glucose by tumours can be harnessed clinically for diagnosis 
and staging, by assessing the uptake of radioactive fluorine-labelled glucose (18F-
fluorodeoxyglucose) uptake by positron emission tomography (PET)-based imaging 
(Almuhaideb, Papathanasiou and Bomanji, 2011). 
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As result of increased glucose uptake, there is also an accumulation of glycolytic 
intermediates needed for macromolecule biosynthesis. This additional carbon can be 
diverted into several pathways stemming from glycolysis, where it is utilised in the synthesis 
of lipids, proteins and nucleotides. An example of this is the flux of carbon through 
phosphoglycerate dehydrogenase (PHGDH) for de novo serine production (Locasale and 
Cantley, 2011). In addition to ATP production and macromolecule biosynthesis, glucose can 
also support the production of reducing equivalents in cancer cells, where increased flux 
into the pentose phosphate pathway allows for NADPH generation (Ward and Thompson, 
2012). Furthermore, one of the major consequences of the Warburg Effect is the enhanced 
regeneration of NAD+ from NADH through the reduction of pyruvate to lactate (Heiden, 
Cantley and Thompson, 2009), which sustains the high rates of glycolysis (Le et al., 2010) 
and reduces the requirement of NADH oxidation by the tumour mitochondria. Pyruvate is a 
major metabolic hub, which as well as being reduced to lactate can be transaminated to 
form alanine for protein synthesis, or oxidised in the mitochondria by pyruvate 
dehydrogenase (PDH) to form acetyl coenzyme A (CoA), which then condenses with 
oxaloacetate to produce citrate in the first step of the tricarboxylic acid (TCA) cycle (Hay, 
2016). 
1.6.2 Glutamine metabolism 
 
As mentioned in the above section cancer cells require a plethora of additional nutrients in 
order to maintain their enhanced proliferation and survival in a sub-optimal environment. 
Although not technically an essential amino acid, glutamine is required by most cancers in 
significant quantities (Wise and Thompson, 2010), as it serves as a major anabolic carbon 
and nitrogen source for synthesis of macromolecules, a source of high energy electrons for 
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ATP production and the regulation of ROS homeostasis via glutamate through the synthesis 
of glutathione. Cells import glutamine through neutral amino acid transporters, such as the 
alanine/serine/cysteine/threonine transporter 2 (ASCT2; SLC1A5 (Carr et al., 2010). 
Alongside the fates above, glutamine may also be exported from the cell through certain 
antiporters, such as the L-type amino acid transporter (LAT1 or SLC7A5), in exchange for 
leucine or other branched chain amino acids (BCAAs), which has been shown to be an 
important compensatory mechanism in leukaemic cells after glycolytic inhibition (Polet et 
al., 2016). Furthermore, cytosolic glutamine can be used in the synthesis of glutamate, 
where the amide group can either be removed by glutamine phosphoribosyl pyrophosphate 
amidotransferase (GPAT) for nucleotide biosynthesis (Metzler, Gfeller and Guinet, 2016), 
glutamine fructose-6-phosphate amidotransferase 1 (GFAT1) for hexosamine biosynthesis 
(Oikari et al., 2016), or primarily by glutaminase (GLS).  
1.6.3 Glutamate metabolism 
 
Glutamate has diverse roles within the cell, where it can be utilised as an amino acid, or 
donate its amine group in the biosynthesis of other non-essential amino acids (NEAAs) and 
nucleotides. NEAAs synthesis is directed through a group of diverse transaminases, which 
catalyse the transfer of the amine group of glutamate to α-ketoacids; examples being OAA, 
3PG and pyruvate, while in the process producing aspartate, serine, and alanine, 
respectively (Yang et al., 2018). These NEAAs can then be used in several ways, where 
aspartate is a precursor for asparagine as well as all nucleotides, and serine is a precursor 
for glycine (as well as a major donor of 1C units for nucleotide synthesis). Independent of 
transaminase activity, glutamate is also involved in the synthesis of the NEAA proline, which 
occurs in a two-step enzyme-catalysed reduction (Wu et al., 2011; Coloff et al., 2016). 
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Recent studies have increased our understanding of how cancer cells utilise glutamine for 
intermediary carbon metabolism. A large part is of this metabolism is through the 
deamination of glutamate to form α-ketoglutarate (αKG), which is either produced through 
transaminase enzymes, or by glutamate dehydrogenase (GDH) - an enzyme whose activity 
results in the NAD(P)+ dependent release of the amine group as ammonia. Glutamate-
derived αKG is able to supplement TCA cycle metabolism and sustain energy production in 
proliferating cancer cells (Weinberg et al., 2010). Evidence from several cell types highlights 
the importance of αKG directed anaplerosis (Forbes et al., 2006; Villar et al., 2015; Yang, 
Venneti and Nagrath, 2017). Moreover, this αKG may also be used to fuel lipid synthesis, 
which under certain conditions can occur independently of oxidative TCA cycle metabolism. 
Reductive carboxylation (RC) of αKG allows for the synthesis of citrate and resulting de novo 
lipogenesis through IDH1 and 2, and ACO 1 and 2, in an NADPH-dependant manner. RC was 
first defined in a brown adipocyte cell line (Yoo et al., 2008) and is now known to be 
enhanced under hypoxic conditions (Metallo et al., 2012). Moreover, glutamine-derived 
malate can be used to synthesise pyruvate, through the activity of malic enzyme (ME) (Dey 
et al., 2017; Murai et al., 2017). This process results in NADPH production, supporting 
cellular redox and reductive reactions (DeBerardinis et al., 2007). Mitogen stimulation has 
also been shown to stimulate similar effects in lymphocytes (Brand, 1985) and the use of 
13C-labelled glutamine identified glutaminolysis as an anaplerotic process in gliomas 
(DeBerardinis et al., 2007), although this has since been refined (Tardito et al., 2015). 
In addition, glutamate maintains the pool of intracellular glutathione (GSH) - a tripeptide 
produced from cysteine, glutamate and glycine. The production of GSH from these amino 
acids requires a two-step, ATP dependant reaction: the first of which involves the rate-
limiting enzyme glutamate cysteine ligase (GCL), which converts glutamate and cysteine to 
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gamma-glutamylcysteine. The second step is then catalysed by glutathione synthetase 
(Harris et al., 2015). 
 
 
1.6.3.1 Glutamate as a neurotransmitter 
 
Glutamate is the major excitatory neurotransmitter in the central nervous system (CNS), its 
activity under normal circumstances being governed by numerous transporters, along with 
ionotropic and metabotropic receptors (Miladinovic, Nashed and Singh, 2015).  More 
recently however, glutamatergic dysregulation has been implicated in gliomas (de Groot and 
Sontheimer, 2011; Robert and Sontheimer, 2014). Glioma cells have been previously shown 
to export cytotoxic concentrations of glutamate in vitro (Ye and Sontheimer, 1999), which 
helps promote the growth of malignant gliomas via glutamate receptor signalling (Takano et 
al., 2001), and may result in neuronal cell death, allowing for the expansion of tumour into 
the necrotic void (Sontheimer, 2008). The release of glutamate by many tumour types, 
including gliomas, breast, melanoma and prostate cancers, is largely mediated via system 




− transport (xCT; SLC7A11) (Sharma, Seidlitz and Singh, 2010; de Groot and Sontheimer, 
2011). Increased xCT activity conveys additional benefit to cancer cells via cystine uptake and 
support of GSH synthesis. 
In addition to its role as an excitatory neurotransmitter, glutamate is also a substrate for the 
synthesis of the inhibitory neurotransmitter Gamma-aminobutyric acid (GABA). The 
synthesis of GABA from glutamate is catalysed by the enzyme glutamate decarboxylase 
(GAD) (Bak, Schousboe and Waagepetersen, 2006). The role of GABA in the context of 
cancers has been relatively unexplored, and the few studies into its role are conflicting. It 
has been reported that pancreatic cancers with GABA-A receptor overexpression 
demonstrated amplified growth through GABA signalling (Takehara et al., 2007). However, 
an opposing role in colon carcinoma cells has also been described (Miao et al., 2010). 
Furthermore, the pattern of GABA receptor gene expression is predictive of prognosis in 
non-small cell lung cancer, where a low expression of GABRA3 with a high expression of 
GABBR2 predicts a better outcome in these patients (Zhang et al., 2013). There is clearly 
more research required on the biological effects of GABA production in tumours.  
1.6.2.1 Glutaminase  
 
The amidohydrolase enzyme glutaminase (GLS) is a crucial component of glutamine 
metabolism, where it catalyses the hydrolysis of the γ-amino group of glutamine to form 
glutamate and ammonia (Yuneva et al, 2007). The resulting ammonia can be utilised to 
produce carbamoyl phosphate, or may simply diffuse from the cell. The GLS family comprise 
of two isozymes which are encoded on separate genes located on different chromosomes: 
the Kidney (K-type) GLS gene, which is situated within chromosome 2 and encodes two 
variants KGA and GAC (Figure 1.4 A), and the liver (L-type) GLS2 gene, which is positioned on 
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Figure 1.5  Genomic structure of GLS1 and GLS2 genes and mRNA transcripts. 
Introns are depicted as solid black lines and exons as numbered red (GLS1) or 
blue (GLS2) boxes. mRNA reveals differences between splice variants, KGA and 
GAC for GLS1 and GAB and LGA for GLS2. 
A 
B 
chromosome 12 and encodes for an additional two isozymes, LGA and GAB (Figure 1.4 B). 
GLS1 has been shown as being highly expressed in tumour cells, where it aids proliferation 
and oncogenic transformation. GLS2, however, is commonly down regulated in tumours and 
is often described as tumour suppressive, although, it is important to note that this does not 











In MB, the same is likely to apply, given the oncogenes and tumour suppressors associated 
with this tumour. C-MYC expression has a strong, indirect effect on GLS1 expression through 
the repression of microRNA-23A and microRNA23-B, which act to inhibit GLS1 expression. 
Furthermore, it has also been reported that GLS2 is a p53 target gene, and is regulated 
through three p53 consensus DNA-binding elements within the promotor region. This was 
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confirmed in both tumour and non-tumour cells, where the degree of its regulation altered 
depending on cell type and levels of stress (Suzuki et al, 2010).  
It seems key to elucidate the opposing roles of these proteins and to investigate why 
different GLS isoforms have evolved. The weight of data suggests that GLS1 expression 
positively correlates with heightened proliferation, while GLS2 expression appears to be 
associated with non-proliferating cells (Campos-Sandoval et al., 2015). In view of that, it is 
no surprise that increased GLS1 expression has been observed in several cancers, including 
lung, breast, brain, B cell lymphomas and cervical (Szeliga and Obara-Michlewska, 2009). 
However, GLS1 exists as two splice variants and it is also important to elucidate whether 
their expression or relative activity differs in cancer. KGA and GAB are typically referred to 
as mitochondrial glutaminases, however, this nomenclature appears inaccurate as 
increasing number of studies have shown differential expression in the cytosolic fractions of 
cells (Cassago et al., 2012; Campos-Sandoval et al., 2015). The nomenclature also generates 
confusion within the literature, with some studies referring to GLS1 as KGA, encompassing 
GAC along with it, therefore disregarding these as two separate variants. Few studies have 
examined the phenotypic differences between KGA and GAC, although, the identification of 
differential intracellular localisation highlights the need for increased investigations. One 
important aspect to consider will be the compartmentalisation of glutamate and the role 
this may play in different metabolic pathways. 
Unlike GLS1, GLS2 is commonly silenced in gliomas through promoter methylation (Szeliga 
and Obara-Michlewska, 2009). In fact, overexpression of GLS2 in glioblastoma cell lines was 
shown to elicit a reversion of their tumourigenic phenotype (Szeliga et al., 2014). The 
visualisation of GLS2 in the nucleus (Olalla et al., 2002) has fuelled much debate about its 
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role in transcriptional reprogramming- indeed it is possible that the overexpression of GLS2 
may have reduced the malignant phenotype in a glioma cell line through direct alteration of 
the transcriptome (Suzuki et al, 2010). However, there is currently a paucity of data 
regarding this putative nuclear role of GLS2.  As mentioned previously, GLS2 expression is 
commonly lost in gliomas, despite high expression in healthy brain. In agreement with this 
observation, GLS2 is also greatly reduced in other brain tumours, as well as hepatocellular 
carcinomas, which highlights the clinical implications of this protein and its potential role in 
tumour suppression. However, the behaviour of GLS2 in cancer is more complicated than 
previously assumed, as there are some types of cancer where increased GLS2 expression is 
observed, conferring resistance to current therapies (Hu et al., 2010). Furthermore, GLS2 
expression increases in response to oxidative stress or DNA damage in a p53-dependent 
manner, which may be protective through enhancement of mitochondrial respiration and 
therefore, ATP production, and decrease of ROS levels through the increase in cellular 
concentrations of glutathione (Rufián et al, 2015). 
Although, it has previously been suggested that the differing regulation of GLS and GLS2 
may account for their opposing roles in human biology, it is possible that these roles may be 
determined by their structure. GLS2 appears to have greater potential than GLS1 for 
regulation through interactions with other proteins or indeed metabolites, as it contains a 
number of consensus motifs and domains within its structure. It has been found that the 
GAB isoform contains a consensus sequence essential for interaction with PDZ proteins; 
specifically glutaminase-interacting protein (GIP) and α1-syntrophin (Olalla et al., 
2002).Little is known, however, about potential protein: protein interactions of GLS. GLS 
isozymes are therefore thought to differ in their kinetics, regulation and evidence suggests 
that they may have alternative roles in immunological responses. Their differences in 
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activity are largely related to the dependence on inorganic phosphate as an activator; GLS2 
has little dependency, while GLS1 is more dependent for its activity. The relative affinity for 
glutamine has also been established with GLS1 exhibiting a higher affinity. A novel 
characteristic of GLS1 isozymes have also been revealed, where glutamate has been found 
to have an inhibitory effect (De la Rosa et al, 2009).  Surprisingly, the GAB variant of GLS2 
exhibits kinetics reflecting both GLS1 and GLS2 characteristics; GAB displays both low 
dependence on inorganic phosphate for its activity, but was surprisingly inhibited by 
glutamate (Szeliga et al, 2013). This emphasises the plethora of effectors that may modulate 
the activity of GLS isozymes and may go some way to explain how cancer cells can 
selectively express GLS isoforms that support different phenotypes - whether ‘go’ or ‘grow’.  
1.6.3 The role of genetics on cancer metabolism 
 
Mutations in tumour suppressors and oncogenes are the basis of cancer. Recent work, 
however, has revealed a tightly regulated network between oncogenic mutations and 
resulting metabolic phenotypes. For instance, p53 is a potent regulator of metabolism, 
where it is able to elicit effects at several points of both glycolysis and oxidative 
phosphorylation. Alterations in the flux through glycolysis is achieved through activation of 
p53-induced glycolysis and apoptosis regulator (TIGAR), which inhibits PFK-1 activity 
diverting glucose 6-phosphate into the pentose phosphate pathway (PPP) (Bensaad et al., 
2006), while increased oxidative phosphorylation is mediated through p53-induced 
cytochrome c oxidase assembly factor SCO2 (Matoba et al., 2006). As introduced earlier ( 
section 1.6.2.1), p53 induces GLS2 expression, increasing glutamate and αKG levels and 
enhances the rate of the TCA cycle (Hu et al., 2010).  These metabolic changes through p53-
dependant target gene expressions may provide a mechanism of reducing tumorigenesis, by 
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resisting ‘Warburg metabolism’.  However, they may also support tumourigenesis after 
initial oncogenic stimulus through increased resistance to oxidative stress and enhanced 
anabolism. The MYC proto-oncogene is frequently activated in human cancers and can also 
regulate genes involved in cellular metabolism, such glutamine metabolism (Wise et al., 
2008), mitochondrial biogenesis (Morrish et al., 2010) and lipid synthesis (Eberlin et al., 
2014). Furthermore, tumourigenic mutations seldom arise in isolation and the combination 
of mutations in a given cancer cell can alter its metabolic network. Comprehending the 
mechanisms by which specific mutations alter cellular metabolism is important to 
understand the metabolic dependencies and/or deficiencies in specific tumours, which may 
be exploited therapeutically. Many of the mutations in tumours result in similar changes in 
metabolism, thus, metabolic targeting rather molecular targeting may be more successful in 
a range of tumours. An example of this was demonstrated In the case of Kirsten rat sarcoma 
viral oncogene homolog (KRAS) mutations in pancreatic ductal adenocarcinoma (PDAC) 
(Biankin et al., 2012), which despite occurring in around 95% of tumours, has no effective 
targeted treatments (Kamisawa et al., 2016). Several studies have highlighted oncogenic 
KRAS as a major player in regulating tumour metabolism, where is has been shown to 
stimulate glucose uptake (Yun et al., 2009), alter glutamine metabolism (Son et al. 2013), 
induce autophagy and macropinocytosis (Mann et al., 2016).   
1.7 Metabolism in Medulloblastoma 
 
Metabolism in cells undergoing neural development appears to share several of the traits 
also observed in cancer, including an increase in aerobic glycolysis (Warburg effect) and 
increased lipogenesis (Bhatia et al., 2011).  This is not surprising seeing as neurogenesis, 
similarly to cancer, requires rapid proliferation.  These metabolic phenotypes observed in 
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neural progenitors are preserved or reinstated in MB, which arises from progenitor-derived 
brain cells.  
During the first 12 months of life, cerebellar granule neuron progenitors (CGNPs) proliferate 
in a germline matrix along the external granule layer (EGL) of the cerebellum. This 
proliferation is prompted by the introduction of sonic hedgehog (shh) signalling, which is 
halted upon completed cerebellar development, but may continue when shh signalling is 
aberrantly controlled, thus predisposing to MB (Noguchi et al, 2015). In addition to 
proliferation, shh signalling alters CGNPs metabolic phenotype by increasing aerobic 
glycolysis and lipogenesis, with a concurrent decrease in fatty acid oxidation. To achieve 
this, shh transcriptionally regulates proteins needed for lipid synthesis, such as acetyl-CoA 
carboxylase 1 (ACC1) and fatty acid synthase (FASN), medium chain acyl-CoA dehydrogenase 
(MCAD) and also acyl-CoA oxidase 1 (ACOX1) (Foster et al, 2012). This transcriptional 
regulation is largely controlled through shh-dependent stimulation of E2F1 through 
Retinoblastoma protein (RB) modulation. A shh-driven MB transgenic mouse model, which 
recapitulates the lipid deposition observed in patient tumours, was used to investigate 
whether, ex vivo, this could be observed in CGNPs. When explanted CGNPs were cultured in 
shh-rich media, the same transcriptionally altered phenotype as outlines above was 
observed, confirming the signalling mechanism responsible for this phenotype. 
Furthermore, role of the Rb-E2F axis in MB phenotype, downstream of shh, was also noted: 
after knocking down of E2F1 a reduction in shh-mediated expression of FASN and MCAD 
was recorded in these CGNP cells (Bhatia et al., 2011). As further evidence, palmitate 
oxidation was monitored in the shh-MB tumour model- the decreased oxidation was 
rescued upon E2F1 knockdown.  Therefore, Shh resulted in synthetic lipid metabolism in 
CGNPs rather than being catabolic, and this switch was facilitated by E2F1 and negatively 
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controlled by Rb. This metabolic phenotype is upheld in MB-bearing mice where it has been 
shown that therapeutic inhibition of FASN or the Rb-E2F axis slowed tumour progression 
and lengthened the overall survival in these mice (Bhatia et al., 2012).  
The similarities between energy metabolism during neurogenesis and MB can be found 
within the Peroxisome Proliferator-Activated Receptor-γ (PPARγ) signalling axis. In 
particular, a study showed that E2F1 is able to activate PPARγ, which in turn leads to the 
upregulation of several glycolytic enzymes, such as Pyruvate kinase M2 (PkM2), Hexokinase 
2 (HK2), and GLUT4 (Bhatia et al., 2012). In the same study, it was also demonstrated that 
the blockade of PPARγ significantly inhibited tumour cell growth, thereby prolonging mouse 
survival, similarly to that observed with FASN and Rb-E2F inhibition. 
It is therefore understood that MB is a heterogeneous collection of tumours; with 
potentially 12 subgroups (previously seen in section 1.3.5). However, much of the described 
metabolic regulation and effectors have been focused on SHH signalling, despite this 
subgroup only constituting around a third of all cases of MB. This raises the question of 
whether the metabolic phenotypes described in CGPNs and SHH MB bear resemblance to 
the other subgroups, given their suggested different cell type of origin. However, given that 
many of the metabolic phenotypes observed in CGPNs, including that of high glycolytic flux, 
are common to most if not all progenitor/stem cells, it is likely that all neural progenitors 
that are the origins of MB share similar metabolic networks (Ito and Suda, 2014). Despite 
cerebellar proliferation being dependent on SHH signalling, HK1 is not expressed in any 
progenitor regions within the postnatal brain, implying a shift to HK2 can be initiated by 
various growth factors (Gershon et al, 2013). In relation to this, PKM2 integrates the 
signalling pathways from several growth factors in order to decrease PK activity. Therefore, 
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CGPN activation of aerobic glycolysis in response to SHH signalling could be a generic 
reaction of these cells to individual growth factors that drive their proliferation.  
As well as SHH signalling, there are increasing data indicating that WNT/β-catenin signalling 
is able to regulate metabolism in tumour cells. It was established in ovarian cancer that a 
significant number of genes controlling metabolism- in particular glutamine and fatty acid 
metabolism- were found to be transcriptional targets of β-catenin. Recent studies have 
uncovered the role of the canonical WNT pathway in cancer cell metabolism (Wetering et al, 
2002). For example, in hepatocarcinoma, WNT signalling was found to increase aerobic 
glycolysis by suppressing mitochondrial respiration through the reduction of cytochrome c 
oxidase. It has been well documented that WNT signalling transcriptionally increases C-MYC 
(Calvisi et al., 2001) In fact N-MYC and its homologue C-MYC are vital in the regulation of 
progenitor cell function in neural tissue, where N-MYC is commonly activated in all subtypes 
of MB and C-Myc plays a significant role in Grp3 MB (Roussel and Robinson, 2013). 
Interruption of the MYC-MAX complex in CGNPs prevented the shh-dependent initiation of 
aerobic glycolysis and proliferation.  This evidence strongly supports the notion that MYC 
may be a common metabolic conversion point between subgroups, that may act 
downstream of multiple mitogenic signalling pathways.  
Importantly, SHH and WNT pathway stimulation are able to drive MB progression by 
activating downstream oncogenes, such as N-MYC. Understanding the mechanisms that 
regulate the metabolism of cerebellar progenitors during development may thus lead to 





1.8 Methods used to investigate cancer metabolism 
 
1.8.1 Metabolomics 
Although genomics provide a plethora of information regarding cell genotype, it does not 
reveal the phenotypical nature of cancers. Instead, it provides insights into the phenotype 
which is ‘likely’ to occur. Metabolomics describes the field of study dedicated to the 
exploration of the metabolome within a biological system allowing for a more in depth 
understanding of cellular functions in cancer, allowing us to measure biological ‘end points’. 
Technologies dedicated to the study of metabolomics are typically founded on sensitive 
spectroscopic and spectrometric approaches, such as chromatography, mass spectrometry 
(MS) and nuclear magnetic resonance (NMR) spectroscopy.  
Metabolic profiles are becoming increasingly seen as a way of stratifying tumours. For brain 
tumours particularly it is beneficial as it can be conducted through non-invasive imaging. A 
retrospective study analysed patients with MB using 1H magnetic resonance spectroscopy 
(MRS) and identified that glutamate was a marker of survival across all MB subgroups 
(Wilson et al., 2014). 
1.8.2 Stable isotope tracing  
Unless ‘essential’ within a system, metabolites can be produced by several interconnecting 
pathways. One example of this is the synthesis of glutamate, which can be synthesised or 
utilised by 200 known reactions, spanning 55 metabolic pathways (Fan et al. 2012). This 
makes it difficult to distinguish which pathway is responsible for eliciting changes observed 
in glutamate concentrations, and therefore, highlights the importance of being able to 
determine the origin or ‘destination’ of any given metabolite. This can be achieved with 
isotopic label incorporation methods, which rely on the use of naturally-occurring 
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metabolites, enriched in one or more heavy isotopes (Antoniewicz, 2013). The most popular 
isotope used today is 13C, owing to the significant proportion of metabolites containing 
carbon backbones, and the fact that it has a non-integer spin and a detectably different 
mass compared to 12C, allowing it to be measured using spectroscopic and spectrometric 
techniques. Other viable tracers include 15N and 18O, which are gaining popularity.  To 
perform these analysis, isotopically enriched tracer metabolites, such as glutamine are fed 
to cells, resulting in metabolites downstream to be enriched with the isotope of choice. The 
differing amounts and ways in which subsequent metabolites can be labelled with stable 











1.8 Manipulating metabolism in the treatment of cancer 
 
Since Otto Warburg’s observation of increased lactate production in aerobic conditions in 
cancer cells (Warburg, 1925), significant studies, including clinical trials, have examined the 
effectiveness of blocking this metabolic pathway to reduce tumour growth, or as a means of 
A B 
Figure 1.6 Isotope labelling. A) example of 13C-U-glutamine isotopic labelling. B) Example 




sensitising tumours to existing treatment. Such effects have been directed towards reducing 
tumours glucose uptake, where Ritonavir (inhibitor of GLUT4) blocks glucose uptake in 
multiple myeloma cells leading to the induction of apoptosis. Ritonavir was also shown to 
decrease the viability of primary myeloma cells and increase sensitivity to doxorubicin 
(McBrayer et al., 2012). Efforts have also been directed towards disrupting tumour 
glycolysis. 2-deoxyglucose (2-DG) is a glucose analogue shown to increase killing of breast 
cancer cells when combined with irradiation or chemotherapeutic treatments  (Aghaee, 
Islamian and Baradaran, 2012). However, an early phase clinical trial with intravenous 
infusions of 2-DG in pancreatic tumour patients were discontinued due to adverse side 
effects (Landau et al., 1958). A significant problem with these therapies lies in the non-
specific nature of targeting glycolysis, highlighting the need for more specific metabolic 
pathway targeting approaches.  
 
1.8.1 Targeting glutamine metabolism. 
It has been shown that many types of cancer cells are sensitive to glutamine starvation, 
including cells derived from small cell lung carcinoma, glioblastoma multiforme and acute 
myelogenous leukaemia (Wu, Arimura and Yunis, 1978).  Glutamine analogues including 6-
diazo-5-oxo-L-norleucine (L-DON), azaserine, and acivicin have also been investigated with 
varying degrees of success. Preclinical testing of each of these agents displayed significant 
cytotoxicity’s in specific tumour types, both in cell lines and in mouse xenograft models 
(Ahluwalia et al., 1990). However, owing to severe toxicities observed in clinical trials, the 
use of glutamine analogues is restricted. Other efforts have been directed towards 
suppressing glutamine uptake in tumour cells with a study demonstrating how the targeting 
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of SLC1A5 with small molecule inhibitors, L-γ-glutamyl-p-nitroanilide and benzylserine 
suppresses the growth of non-small cell lung tumours in vivo (Hassanein et al., 2015).  
 
Due to the importance of glutamine in cancer, substantial efforts have been made to inhibit 
its uptake and resulting metabolism. Reduction of GLS expression through siRNA has been 
shown to reduce ATP while raising intracellular ROS levels in breast cancer, highlighting it as 
a potential target in certain tumours. Furthermore, GLS can be therapeutically targeted with 
small molecule inhibitors such as compound 968 (Wang et al., 2010), CB-839 (Gross et al., 
2014) or the most widely studied GLS inhibitor bis-2-[5–phenylacetamido-1, 2, 4-thiadiazol-
2-yl] ethyl sulfide (BPTES) (Shukla et al., 2012). The use of these inhibitors in the treatment 
of cancers is summarised in table 1.1 
Figure 1.7 Druggable targets in glutaminolysis. Enzymes are shown in blue, 
transporter in green. Inhibitors of these are shown in red. 
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Table 1.1  Inhibitors of GLS1 and their use in the clinic 
BPTES 
 
BPTES specifically inhibits glutaminase 
and suppress tumour growth in several 
preclinical animal models including 
hepatocellular carcinoma (Xiang et al., 
2015), renal cell carcinomas(Shroff et al., 
2015)  and lymphoma (Le et al., 2012) 
CB-839 
 





Compound 968 has been shown to 
suppress oncogenic transformation 
induced by Rho GTPases in fibroblasts. 
C968 also shows synergistic action in 
combination with mTOR inhibitor in 
glioblastoma (Tanaka et al., 2015) 
 
The binding of BPTES to GLS, elucidated through investigations of the crystal structure, is 
through an allosteric pocket at the dimer interface, which results in the stabilisation of the 
tetrameric, inactive form of GLS (Thangavelu et al., 2012).  Several studies have shown the 
effectiveness of BPTES on inhibiting proliferation of tumour cells, including renal cell 
carcinoma (Shroff et al., 2015), hepatocellular carcinoma (Xiang et al., 2015) and in B-cell 
lymphoma (Le et al., 2012). Interestingly, pyruvate carboxylase (PC) expression has been 
shown to determine BPTES efficacy, with higher PC reducing the sensitivity of lung cancer 
cells to BPTES  (Ulanet et al., 2014), suggesting a potential benefit of duel targeting of GLS 
and PC simultaneously. CB-839 is a relatively new derivative of BPTES and is currently in 
phase 1 clinical trials to treat triple negative breast cancer (Gross et al., 2014). However, few 
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other studies have made meaningful progress as of yet. The mode of action of compound 
968 is different to that of BPTES; this inhibitor preferentially binds to the monomeric 
,inactive form of GLS, and as a result prevents the dimerization required for GLS activation 
(Stalnecker et al., 2015). Therefore, compound 968 is unable to inhibit GLS when the 
enzyme is already in an active conformation. The effectiveness of compound 968 has been 
demonstrated in breast cancer, where inhibition prevented Rho GTPase dependant 
oncogenic transformation and exhibited synergistic activity in glioblastoma when combined 
with mTOR inhibitors (Tanaka et al., 2015). Importantly, compound 968 appears to 
demonstrate a reasonable potential therapeutic window, as concentrations that are 
inhibitory in  cancer cells, often show minimal effects upon non-transformed cells (Wang et 
al., 2010). In part, these results can be accounted for the fact that non-transformed cells are 
able to bypass the need for glutaminase, and typically use glucose for oxidative 
phosphorylation. However, as highlighted above, glutamine-derived glutamate has a 
significant physiological role in the brain, through its neurotransmitter activity, which leads 
to side-effects of this treatment. Despite encouraging in vitro results using compound 968, 
use in pre-clinical animal models has been challenging, due to its hydrophobic nature (Katt 
and Cerione, 2014). 
It is interesting to see that different allosteric mechanisms observed between BPTES and 
compound 968 results in differential effects in the treatment of tumours. The inhibition 
differences caused by these compounds on KGA and GAC have not been elucidated yet and 
may be needed to shed light on possible differences observed clinically.  
Unlike GLS1, the therapeutic targeting of GLS2 has been relatively neglected, until more 
recently, due to a lack of specific inhibitory compounds. Lee and colleagues, however, have 
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identified Alkyl benzoquinones as novel inhibitors of GLS2, the use of which leads to 
mTORC1 inhibition and results in reduced tumorigenesis (Lee et al., 2014). It will be 
interesting to see the use of these inhibitors in future studies.  
As a metabolite interlinked with glutamine, proline has received more interest in recent 
times with disruption of this metabolism proving a potential target in the treatment of 
cancers (Phang et al., 2015). The importance of proline is also highlighted by the fact that 
MYC induces its biosynthesis from glutamine (Liu et al., 2012), which was later elucidated to 
be a direct cause of MYC-induced upregulation of Δ1-pyrroline-5-carboxylate (P5C) synthase 
(P5CS), and P5C reductase-1 (PYCR1) (Liu et al., 2015). Inhibition of this proline metabolism 
reduced the growth of a number of tumour cell lines, which was thought to be a result of 
reduced pyridine nucleotide synthesis (Liu et al., 2015).  
 
1.9 Summary  
 
Our molecular understanding of MB tumours has been advanced dramatically over the past 
few years, with invaluable studies from Schwallebe and Cavalli, revealing new MB 
subgroups, each with different prognoses. Despite this, no real success has been made in 
the way of molecular targeting of these tumours, where we know from past attempts that 
primary and secondary drug resistance present significant clinical challenges. In the clinic, 
patients still receive the same treatment regimens, albeit at different intensities, and it is 
clear other attempts must be made to treat these tumours. Glutamate is a predictive 
marker of survival in MB, irrespective of subgroups. This, along with Niklison-Chirou’s study 
last year, highlights the potential importance of glutamine metabolism in these tumours and 
the potential for the clinical targeting of this metabolism.  
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1.10 Thesis aims 
 
This thesis aims to investigate the importance of glutamine metabolism in MB, with added 
emphasis on understanding the impact of increasing glutamate concentrations. We intend 
to identify key glutamine - derived metabolic pathways utilised in MB cell line, with the aim 















































2.1 Cell Lines 
 
All cell lines used were derived from SHH-MB patients. ONS-76 (TP53 WT) cells were 
purchased from the Japanese cell line bank (JCLB), DAOY (TP53 mutant) cells were 
purchased from the American Type Culture Collection (ATCC), and the UW228.3 cells were 
kindly gifted by Professor Steve Clifford (University of Newcastle). All cell lines were cultured 
in DMEM HAMS/F12 (Sigma-Aldrich, D5796) supplemented with 10% FBS (Hyclone Thermo 
Scientific, SV30180.03). Cell lines were maintained using standard procedures in a 37oC 
humidified incubator, 5% CO2 and regularly tested and excluded for Mycoplasma 
contamination using EZ-PCR Mycoplasma Test Kit, (Geneflow, K1-0210). 
2.2 MB patient mRNA expression & survival cohorts 
 
2.2.1. GEO: GDS4471 
 
Clinical and mRNA expression data, from MB patients, was extracted from an online NCBI 
Geo repository (accession number: GDS4471). This Expression profiling array, included 76 
samples, each belonging to the separate MB subgroups; WNT (n=8), SHH (n=11), G3 (n=16) 
and G4 (n=39). Two of the patients did not fit into one of these subgroups and thus, were 
excluded from this dataset.  
2.2.2. GEO: GSE42658 
 
We analysed mRNA-sequence data collected from 9 MB patient samples and 4 CB samples, 
using the NCBI Geo repository accession number: GSE42658. Subgrouping information for 
the 9 MB patients were not attained. A non-parametric t-test with a Mann Whitney post-
test was performed on the data obtained, using GraphPad Prism. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.  
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2.2.3. Newcastle Cohort 
 
Data arising from patients within the Newcastle cohort was provided to us by Professor 
Steven Clifford, University of Newcastle.  
Clinical data allocated to individual patient was downloaded and data regarding sample ID, 
neoplasm histologic grade, overall survival (months) and overall survival status were noted. 
n=240 (WNT n=28, SHH n=58, G3 n=59 and G4 n =95). High and low expression was 
determined by the median expression value for each gene. An overall survival status column 
was generated, with patients who died from their disease were designated ‘1’ and surviving 
patients were entitled ‘0’. Log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon statistical 
tests were performed in all cases; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
2.3. Survival analysis and Kaplan-Meier generation 
 
Microsoft Excel was used to sort the data set by gene expression for each gene and find the 
median gene expression. Median gene expression was used to separate the high and low 
gene expression. GraphPad Prism 7.0 was used to produce Kaplan-Meier survival curves of 
all genes in the gene set. Overall survival (months) and overall survival status data for the 
high and low gene expression groups was entered into the data table. GraphPad Prism was 
used to generate a survival analysis for each survival curve including a Log-rank/Mantel-Cox 






Table 2.1. List of gene names examined 
Gene name Gene description 
ALDH18A1 (P5CS) Aldehyde dehydrogenase 18 family, member A1 (Pyrroline-5-
Carboxylate Synthetase) 
CDO1 Cysteine dioxygenase type 1 
GAD1 Glutamate decarboxylase 1 
GCLC Glutamate—cysteine ligase catalytic subunit 
GCLM Glutamate-cysteine ligase regulatory subunit 
GLS Glutaminase 1 
GLS2 Glutaminase 2 
GLUD1 Glutamate dehydrogenase 1 
GLUL (GS) Glutamine synthetase 
GPX1 Glutathione peroxidase 1 
GRM1 Glutamate receptor, metabotropic 1 
GRM3 Glutamate receptor, metabotropic 3 
GSR Glutathione reductase 
GSS Glutathione synthetase 
OAT Ornithine aminotransferase 
PRODH Proline dehydrogenase 
PYCR1 Pyrroline-5-carboxylate reductase 1 
PYCR2 Pyrroline-5-carboxylate reductase 2 
SHMT1 Serine Hydroxymethyltransferase 1 (cytosolic) 
SHMT2 Serine Hydroxymethyltransferase 2 (mitochondrial) 
SLC1A1 (EAAT3) Excitatory amino-acid transporter 3 
SLC1A2 (EAAT2) Excitatory amino-acid transporter 2 




SLC1A5 Neutral amino acid transporter B 
SLC1A6 (EAAT4) Excitatory amino-acid transporter 4 
SLC1A7 (EAAT5) Excitatory amino-acid transporter 5 
SLC6A1 (GAT1) GABA transporter 1 
SLC7A11 Cystine/glutamate transporter (xCT) 
 
2.4 RNA Silencing 
 
To assess the knockdown in expression of GLS1 and GLS2, cells were seeded at 2.5 x 105 
onto 12-well plates in standard culture conditions. After 24 h, cells were transfected 
following manufacturer’s instructions with non-targeting RNA (siNT) and siRNA targeting 
GLS1 (siGLS1) and GLS2 (siGLS2) (Dharmacon ON-TARGETplus human siRNA; D-001810-10, L-
004548-01-0010 and L-012500-01-0010, respectively) at 25 nM using DharmaFECT 1 
transfection reagent (Thermo Fisher Scientific, T2001-01) for the ONS-76 and UW228.3 cell 








Table 2.2. Table of transfection conditions 
Gene target name Product information siRNA sequence Concentration  
Non-targeting (NT) Dharmacon,  D-001810-10-05 25nmol 
GLS1 Dharmacon SMARTpool CCUGAAGCAGUUCGAAAUA 25nmol 
GLS2 Dharmacon SMARTpool GCUGAAGCAGUGCGCAACA 50nmol 
GAC1 Dharmacon ON-TARGET GGAAGUCUGGGAGAGAAUU 25nmol 
GAC2 Dharmacon ON-TARGET CUAUGAAAGUCUCCAACAUU 25nmol 
KGA1 Dharmacon ON-TARGET CCCAAGGACAGGUGGAAUAUU 25nmol 
KGA2 Dharmacon ON-TARGET CUGGAAGCCUGCAAAGUAAUU 25nmol 
 
24 h, 48 h and 72 h post transfection, cells were lysed for protein to evaluate efficiency of 
gene knockdown. All transfections were carried out 48 h post seeding and all experiments 
were terminated approximately 72 h from transfection.  
2.5 mRNA extraction 
 
Total RNA was extracted from the ONS-76, DAOY and UW228.3 cell lines using the RNeasy 
Mini Kit (Qiagen, 74104) according to the manufacture’s protocol. Cells were lysed in RLT 
buffer (350 µL), scraped and collected. 350 µL of 70% ethanol was added to each sample 
and were subsequently transferred to RNeasy Mini spin columns and centrifuged for 15 secs 
at 8000 G. RW1 Buffer (350µL) was added to each column and centrifuged for 15 secs at 
8000 g. Buffer RW1 (350µL) was added to each column and centrifuged for 15 seconds at 
8000 g. Buffer RPE (500 µL) was added to each column and centrifuged for 15 seconds at 
8000 g. Buffer RPE (500 µL) was added to each column and centrifuged for 2 minutes at 
8000 g. RNase-free water (30 µL) was added to each column and centrifuged for 1 minute at 
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8000 g to elute the RNA. The quality of the extracted RNA was assessed with a ND-1000 
Nanodrop. 
2.6 Quantitative real-time PCR 
 
Following extraction, 1 µg RNA per sample was subjected to reverse transcription using 
Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV-RT) kit (Promega, M1701). 
10 µL of the resulting cDNA was used with TaqMan® gene expression master mix (AB, 
4369016) for quantitative real-time PCR using AB 7500 Real Time PCR System. The following 
primers and probes were used: GLS1 (Hs01014020_m1), GLS2 (Hs00998733_m1), KGA 
(Hs04969278_s1), GAC (Hs01022163_m1) and ACTIN (Hs00157387_m1) (ThermoFisher 
Scientific). The expression of GLS1, GLS2, KGA and GAC were normalised to actin as 
housekeeping gene. Comparative analysis across samples was calculated using the 2-ΔΔCT 
method. 
 
           Table 2.3 Table of Taqman probes for qPCR 
Gene target name Product number Application 
Actin Hs00157387_m1 FAM-MGB 
GLS1 Hs01014020_m1 FAM-MGB 
GLS2 Hs00998733_m1 FAM-MGB 
GAC Hs01022163_m1 FAM-MGB 







Cells were washed with 1x PBS and lysed directly into 100 µL 1x Laemmli buffer (Sigma-
Aldrich, S3401-1VL), heated at 100oC for 10min, and loaded on 12% acrylamide gels for SDS-
PAGE. Following SDS-PAGE, proteins were transferred electrophoretically onto 0.1 µm 
nitrocellulose membrane (GE Healthcare, 10600000) at 100 V for 90 min. The blots were 
blocked in PBST buffer containing 5% (w/v) non-fat dry milk for 1h, and then incubated with 
the following specific primary antibody diluted in blocking buffer at 4oC overnight (see table 
for antibody spec). All antibodies were diluted in 5% milk. Membranes were washed three 
times in PBST and incubated with HRP-conjugated secondary antibody for 1 h at room 
temperature (Cell Signalling secondary anti-mouse #7076 and anti-rabbit #7074 were both 
diluted 1:4000 in 5% milk). Membranes were washed three times and developed using EZ-
ECL enhanced chemiluminescence detection kit (BI, 20-500-120). All western blots are 
representative of two experiments unless otherwise indicated. 
Table 2.4 Antibodies used for western blotting 
Antibody Species Concentration Supplier (product code) 
Anti-GLS1 Rabbit 1:3000 Abcam, ab93434 
Anti-GLS2 Mouse 1:500 Abcam, ab150474 
Anti-PYCR1 Rabbit 1:5000 Proteintech, 13108-1-AP 
Anti-PYCR2 Rabbit 1:1000 Proteintech, 17146-1-AP 
Anti-Actin Mouse 1:2000 Sigma, A4700 
Anti-Mouse Goat 1:4000 Cell signalling, 7074S 




2.7.1 Western blot densitometry 
 
Western blot band density was analysed to further assess protein knockdown. Developed 
blots were scanned and imported into imageJ. The density of the protein bands for each 
sample was normalised to the density of the corresponding Actin band and plotted in 
GraphPad Prism 7.0. 
2.8 Mitochondria isolation. 
 
Isolation was carried out according to Frezza et al, 2007.  
10x106 cells were frozen and subsequently thawed (to increase yield). Cells were then 
resuspended in 2-3ml of IBc buffer (10% Tris/MOPS, 1% EGTA/Tris, 20% 1M sucrose and 
69% MiliQ H2O) and transferred to a glass vial. The sample was homogenized at 1600rpm for 
5mins on ice, washed with 1ml IBc buffer and subsequently transferred to centrifuge tubes. 
Homogenates were centrifuged at 800g for 8mins at 4◦C and supernatants were transferred 
into fresh centrifuge tubes. The supernatants were then centrifuged at 10000g for 15mins in 
order to pellet the mitochondria. The protein concentration of the mitochondria (pellet) and 
cytosolic fraction (supernatant) were determined using a Pierce™ BCA Protein Assay Kit 
(Thermofisher, 23225).  
2.9 High-resolution respirometry 
 
High-Resolution Respirometer (Oroboros Oxygraph-O2k) was used to determine the oxygen 
consumption of intact MB cells. 2X106 of ONS-76, DAOY and UW228.3 cells were 
resuspended in approximately 2.5mL of DMEM/F12. Cell suspensions were then added to 
individual respirometer chambers for approximately 10 min to allow the respiratory flux to 
reach steady state levels.   
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The following parameters (Figure 2.1 A) were measured: Routine oxygen consumption (no 
use of inhibitors); ATP synthase-independent respiration in the presence of oligomycin, 
which allows for  the measurement of oxygen consumption uncoupled to ATP synthesis 
(leak); Oxygen consumption inhibited by the presence of oligomycin (coupled); Oxygen 
consumption with carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP- titrated in 
1 μM steps) to measure the maximal oxygen consumption rates upon stimulation of the 
electron transfer system efficiency (ETS); residual oxygen consumption (ROX) in the 
presence of rotenone (NADH dehydrogenase inhibitor) and antimycin A (AA) (cytochrome 
bc1 inhibitor). Data acquisition and analysis were carried out with DatLab (Oroboros 
Instruments, Innsbruck, Austria). An example respirometry acquisition can be seen in Figure 




















Figure 2.1. High-resolution respirometry. A) Inhibiting specific complexes in the electron 
transport chain. B) example data demonstrating high-resolution respirometry of the ONS-76  cell 





5 µM sections cut from 6 paraffin-embedded SHH-MB tumour samples were mounted on 
SuperFrost® Plus slides (ThermoFisher Scientific, 10143560). The following antibodies and a 
VECTASTAIN® ELITE® ABC Kit (PK-6100) were used for immunohistochemistry with 3,3’-
Diaminobenzidine (DAB)  as a chromogen. Slides were first placed in xylene for 10 minutes, 
in order to dewax the sample. Rehydration of the tissue was achieved by placing slides in 
100% EtOH for 10mins and then gradually introducing the sample to water (25% for 2min, 
50% for 2min and 100% for 10min). Slides were immersed in 0.3% hydrogen peroxide (1:100 
dilutions of 30% H202 in dH20) for 15 minutes and then washed in water for 10mins. Heat 
induced epitope retrieval was achieved by incubating tissue in citrate buffer (0.63g sodium 
citrate, 0.125g citric acid and 500ml dH20) for 20min at 96°C using a water bath. Slides were 
left to cool at room temperature for 30min and washed in water. Blocking of non-specific 
proteins was achieved by adding horse serum for 1 h and primary antibody concentrations 
(refer to table 2.5) were subsequently added for 1 h. Slides were washed in PBST for 30mins 
before being incubated in secondary antibody (depending on primary antibody species) for 
30min. Samples were incubated with VECTASTAIN ABC reagents for 30 min. DAB (3, 3’-
diaminobenzidine) chromogen was applied to slides for a predetermined amount of time. 
Finally, the slides were further washed for 30min and then counterstained with hemotoxylin 
for 10min.  Table 2.1 shows the antibodies, dilution and antigen retrieval method employed 




Table 2.5 Antibodies used for IHC staining of hypoxia marker (CAIX) and the glutamate-cystine 
antiporter (SLC7A11) 
Antibody Supplier (product code) Dilution Antigen retrieval method 
Anti-CAIX Abcam (ab15086) 1:200 Heat retrieval in citrate buffer (pH6.0) 
Anti-SLC7A11 Abcam (ab37185) 1:200 Heat retrieval in citrate buffer (pH6.0) 
 
Samples were then mounted using DPX and Images were acquired with a Leica DM400B 








Figure 2.2. H&E staining of MB patient tissue. All patient samples were confirmed as being SHH-
derived MB tumours, at the Birmingham children’s hospital (BCH). 
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2.11 Stable isotope Tracing 
 
Basic formulation DMEM media (Sigma, D5030) was supplemented with the relevant tracer 
13C6 glucose (Sigma, 389374) or 
13C5 glutamine (Sigma, 605166) at 10 mM and 2 mM 
respectively, along with the same concentration of corresponding unlabelled glutamine or 




Cells were seeded at 10 x 104 onto 6-well plates in standard culture conditions and were 
transfected after 24 h with non-targeting RNA (siNT) and siRNA targeting GLS1 (siGLS1), 
GLS2 (siGLS2), GAC (siGAC) or KGA (siKGA). Concentrations of siRNA can be seen in table 2.2. 
After overnight incubation, media was changed to basic formulation DMEM (flux media) 
containing 2mM 13C5 glutamine for a further 24h. For hypoxic experiments, relevant plates 
were transferred to hypoxia (1 % O2) chambers for 24h.  
At the conclusion of tracer experiments, cells were washed twice with ice-cold 0.9% saline 
solution and subsequently quenched with 0.5 mL pre-chilled methanol (-20oC). After adding 
an equal volume of ice-cold HPLC-grade water containing 0.5 µg/mL D6-glutaric acid (C/D/N 
ISOTOPES INC, D-5227), cells were collected with a cell scraper and transferred to tubes 
containing 0.5 mL of chloroform (-20oC). The extracts were shaken at 1400 rpm for 15 min at 
4oC and centrifuged at 16,000 g for 15 min at 4oC. Equal volumes of the upper aqueous 
phase was collected and evaporated in GC glass vials under vacuum at -4oC using a 
refrigerated CentriVap Concentrator (Labconco). Metabolite derivatization was performed 
using an Agilent autosampler. Dried polar metabolites were dissolved in 15 µl of 2% 
methoxyamine hydrochloride (Sigma-Aldrich, 226904) in pyridine (Thermo Fisher Scientific, 
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25104) at 45oC. After 60 min, an equal volume of 2,2,2-trifluoro-N-methyl-N-trimethylsilyl-
acetamide + 1% chloro-trimethyl-silane (Sigma-Aldrich, T228575) was added and 
metabolites were incubated for 30 min at 45oC.  
GC-MS analysis was performed using an Agilent 6890GC equipped with a 30 m DB-35MS 
capillary column. The GC was connected to an Agilent 5975C MS operating under electron 
impact ionization at 70 eV. The MS source was held at 230oC and the quadrupole at 150oC. 
The detector was operated in scan mode and 1 µL of derivatised sample was injected in 
splitless mode. Helium was used as a carrier gas at a flow rate of 1 mL/min. The GC oven 
temperature was held at 80oC for 6 min and increased to 325oC at a rate of 10oC/min for 4 
min. The run time for each sample was 59 min. For determination of the mass isotopomer 
distributions (MIDs), spectra were corrected for natural isotope abundance. Data processing 
from raw spectra to MID correction and determination was performed using 
MetaboliteDetector software (Hiller et al., 2009). 
2.12 SRB assay 
 
Cells were fixed in 20% (v/v) ice-cold trichloroacetic acid solution (TCA) (Sigma-Aldrich, 
T0699) for 20 min at 4oC. Plate wells were washed with water and once dry, intracellular 
protein was stained using 0.4% (w/v) sulfohodamine B (SRB) (Sigma-Aldrich, 230162) in 1% 
acetic acid for 10 min at room temperature. After washing with 1% acetic acid to reduce 
non-specific staining, SRB was dissolved in 50 mM Tris/HCl pH 8.8 once dry. 100 µL/well was 
aliquoted for quantification by absorbance at 495 nm on FLUOstar Omega (BMG LabTech).  
Final sample absorbance values were determined by calculating the mean blank-corrected 
absorbance for each replicate, where 50 mM Tris/HCl pH 8.8 alone was used as the blank. 
50 
 
2.13 Glutathione measurements. 
 
2.13.1 1D-1H NMR 
 
2 × 106 cells were plated onto three 15 cm dishes (high cell numbers are required for NMR) 
and cultured in DMEM-/HAMS/F12 media. When roughly 80% confluent, cells were 
extracted for 1D-1H NMR spectroscopy. Extractions were performed as per GC-MS protocol, 
however volumes of methanol, water and chloroform were increased to 1.2ml, 0.5ml and 
1.2ml, respectively.  
Extracted samples where then dried and then resuspended in 60 μL 100 mM sodium 
phosphate buffer (pH 7.0) containing 500 μM TMSP [(3-trimethylsilyl)propionic-(2,2,3,3-d4)-
acid sodium salt] and 10% D2O. Samples were vortexed, sonicated for 10min and 
centrifuged briefly twice, prior to being transferred to 1.7mm NMR tubes using an 
automatic Gilson 215 Liquid Handler (Bruker Biospin). 
1D-1H NMR spectra were acquired using a 600- MHz Bruker Avance III spectrometer (Bruker 
Biospin, UK) with a TCI 1.7 mm z-PFG cryogenic probe at 300 K. Spectral widths were set to 
7,812.5, with 16,384 complex data points being acquired. Each sample was automatically 
tuned, matched and then shimmed (1D-TopShim) to a TMSP line width of <2 Hz before 
acquirement of first spectrum. Spectra were analysed using Chenomx NMR suit software, 
where concentrations of glutamine, glutamate and glutathione were determined. 
2.13.2 Determining the GSH/GSSG ratios 
 
Cells were seeded at 10 x 104 on a 12-well plate in standard culture conditions and were 
transfected after 24 h with non-targeting RNA (siNT) and siRNA targeting GLS1 (siGLS1), 
GLS2 (siGLS2), GAC (siGAC) or KGA (siKGA). Concentrations of siRNA can be seen in table 2.2.  
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A Glutathione assay kit (Cayma, 703002) was used to measure GSH:GSSG in all three MB cell 
lines, as per manufacturers guidelines.  
2.14 Hypoxic incubation 
 
To achieve hypoxia cells were incubated in a hypoxic incubator (Don Whitley, H35 
Hypoxystation), at 1% O2, 5% CO2, balance N2, 37
oC and 75% humidity, for the length of time 
indicated in the figure legend. 
2.15 Dose response treatments: 
 
Treatment conditions are described below. Each treatment was optimised using SRB dose 
response curve to acquire the IC50s in each cell line. Control samples were either treated 
with H2O or DMSO, depending on the treatment given. 
2.15.1 H2O2 treatment  
 
15 x 104 cells were plated onto 12-well plates in standard culture conditions. Cells were 
incubated with media containing 10, 50, 100, 300 and 500 µM H2O2 12h later. Cells were 
fixed using the SRB method as described above and the optimum concentration of 50 μM 
was established for further experiments. 
2.15.2 XCT transporter inhibitor- Sulfasalazine (SSZ) 
 
Cells were seeded at 15 x 104 onto 12-well plates in standard culture conditions and 
incubated for 24 h. Cells were treated with 10 μM, 25 µM, 50 μM, 100 µM, 250μM, 500 µM 
and 1mM SSZ and left for 48h. Cells were fixed using the SRB method as described above 





15 x 104 cells were plated onto 12-well plates in standard culture conditions. Cells were 
incubated with media containing 5, 10, 25, 50, 100 µM cisplatin 24h later. Cells were fixed 
using the SRB method as described above and the optimum concentration of 25 μM was 
established for further experiments. 
2.15.4 Irradiation 
 
20 x 104 cells were plated onto 10 cm dishes in standard culture conditions. Cells were 
exposed to varying Gy of radiation using a Cs-137 Irradiator (Model CIS IBL 437). Cells were 
fixed 48 h after, using the SRB method as described above and the optimum exposure of 12 
Gy was established for further experiments. 
2.15.5 BPTES 
 
15 x 104 cells were plated onto 12-well plates in standard culture conditions. Cells were 
incubated with media containing 1, 5, 10, 25 and 50 µM BPTES 4, 8 and 24h later. Cells were 
fixed using the SRB method as described above and the optimum concentrations of 25 μM, 
15 μM and 10 μM were established for 4, 8 and 24h experiments, respectively.  
 
Table 2.6. Summary of treatments  
Treatment  Concentration used Treatment time 
H2O2 500 μM 12 h 
SSZ 250 μM 48 h 
Cisplatin 25 μM 24 h 
Irradiation 12 Gy 12min 
BPTES 10, 15 or 25 μM 24, 8 or 4 h 
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2.16 Measuring changes in cell viability- AnnexinV/PI cell death assay 
 
2.16.1. Sample preparation 
 
Cells were seeded at 5 x 104. Cells were transfected after 24 h with non-targeting RNA (siNT) 
and siRNA targeting GLS1 (siGLS1) or GLS2 (siGLS2). Concentrations of siRNA can be seen in 
table 2.2.  Cells were subsequently treated as per previous methods (refer to table 2.6). 
Positive control and single stain samples were given 500 µM H2O2 (30% w/w: Sigma, H1009) 
2 hours prior to the experimental procedure, to ensure appropriate cell death (+VE control). 
Following treatment, cells were washed with 1x PBS and trypsinised. Media was then added 
to neutralise trypsin activity for 20 minutes before being centrifuged and removed. Samples 
were resuspended in 500 µl 1x AnnexinV Binding Buffer (BD, 556454) prior to incubation 
with 1 µL 1:1000 PI (Life Technologies, V13242) and 5 µL AnnexinV-FITC (BD, 556419) for 10 
minutes.  
2.16.2. Data collection  
 
Analysis was achieved on the LSRFortessa X-20 flow cytometer. Forward scatter (FSC), side 
scatter (SSC), FITC (530 nm wavelength) - which measures AnnexinV- and PE (575 nm 
wavelength) - which measures PI- signals were determined. FITC and PE laser intensities 
were set so the signal intensity of the unstained control sample was below 103. Cross 
channel bleeding was checked through single stain control samples treated with AnnexinV-
FITC or PI only. 10000 events were collected for further analysis.  
2.16.3. Data analysis 
 
Analysis was achieved using the FlowJo software. AnnexinV-FITC and PI gates were set using 
the control population at approximately 90% viability. The percentage of AnnexinV-FITC and 
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PI negative cells represent the viable cell population. Early stage apoptosis is represented by 
Increased AnnexinV-FITC, with late stage apoptosis is represented by increased staining in 
both AnnexinV-FITC and PI. Cells undergoing necrosis were defined as those with increased 
PI staining. The viable cell population for each control was used to measure alterations in 
cell viability between samples. The data was analysed using a one way ANOVA with a Tukey 








Figure 2.3. Example of flow cytometry staining controls for the Annexin-V/PI cell death assay. 
(left) single stain control for AnnexinV-PE, (middle) single stain control for PI, double positive 
control for both stains. 
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2.17. Collagen staining 
 
5 µM sections cut from 6 paraffin-embedded SHH-MB tumour samples were mounted on 
SuperFrost® Plus slides (ThermoFisher Scientific, 10143560). The following antibodies and a 
VECTASTAIN® ELITE® ABC Kit (PK-6100) were used for immunohistochemistry with 3,3’-
Diaminobenzidine (DAB)  as a chromogen. Slides were first placed in xylene for 10 minutes, in order 
to dewax the sample. Rehydration of the tissue was achieved by placing slides in 100% EtOH for 
10mins and then gradually introducing the sample to water (25% for 2min, 50% for 2min and 100% 
for 10min). Van Gieson reagent was then applied to slides for 5mins, then subsequently dipped in 
100% IMS X3 for 2mins each. Slides were then dehydrated and mounted using depex. 
 
 
2.18. Statistical Analysis 
 
Samples sizes and reproducibility for each figure are denoted in the figure legends. Unless 
otherwise noted, all experiments are representative of at least three biologically 
independent experiments in technical triplicate. All error bars represent mean +/- S.E.M, 
unless stated differently in the figure legend. Statistical significance was determined by 
either a one-way ANOVA or two-tailed Student’s t-test using GraphPad Prism 6, where *P < 



















Metabolic pathways involved in glutamate 

















Glutamine acts as a vital amino acid in cancer where by it is able to serve as a carbon and 
nitrogen source in metabolic pathways including; ATP production, the regulation of ROS 
homeostasis (via glutamate by forming glutathione), and biosynthetic reactions. Many of 
these effects are regulated by glutamine-derived glutamate, which is largely controlled 
through GLS enzymes. The GLS family comprise of two isozymes, GLS1 and GLS2, each with 
their own individual splice variants. GLS1 is commonly highly expressed in tumour cells, 
where it has been shown to aid cellular proliferation and oncogenic transformation (Song et 
al., 2017). Conversley, GLS2 is thought to be tumour suppressive, with reduced expression 
observed in a number of tumours (Szeliga et al., 2014). However, the role of GLS2 in cancer 
is arguably more complicated as there are some types of cancer where increased GLS2 
expression is observed, conferring resistance to current therapies (Hu et al., 2010).  
Glutamate, the product of glutaminase activity, has diverse roles within the cell, where it 
can be utilised as an amino acid, donate its amine group for the biosynthesis of non-
essential amino acids (NEAAs), donate amino groups to α-keto acids for essential amino 
acids, or glutamate can contribute towards other amino group-requiring macromolecules, 
such as nucleotides (Newsholme et al., 2003). In addition, glutamate is required to maintain 
the pool of intracellular glutathione (GSH), both as a component of the tripeptide and 
availability of the other two substrates, by driving the biosynthesis of glycine and the import 
of cystine (for cysteine). Metabolism is important in cancer, and it has been observed that 
glutamate is a marker of survival in patients with MB tumours, regardless of subgroup 
(Wilson et al., 2014). Furthermore, the implications of glutamine metabolism have been 
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revealed more recently in MB, where cell lines derived from MB tumours are addicted to 
glutamine.  
In this chapter we investigate the significance of genes involved in glutamine and glutamate 
metabolism and their associated metabolic pathways with regards to their expression and 
their impact on patient survival. We achieve this by assessing several gene databases from 
available online geo data sets (geo: GSE42658 and geo: GDS4471) and a larger patient 
cohort provided by Steve Clifford, University of Newcastle. The aim of this was to identify 
important, novel metabolic genes, in which we could study further. Through in vitro 















3.2.1 Genes encoding glutamine and glutamate related pathway genes are deregulated in MB. 
 
Previous studies by others have suggested that glutamine and glutamate metabolism may 
be altered in MB, and moreover the degree to which it is altered may correlate with patient 
survival (Wilson et al., 2014). We therefore assessed the expression of several glutamine-
related metabolic genes and the result of this on patient survival, using three independent 
databases (Newcastle cohort and an online database, GEO: GSE42658 and GEO: GDS4471, 
respectively). We noted that in all cases, expression of the transporters responsible for 
glutamate uptake, EAAT1 (Figure 3.2.1) and EAAT2-4 (supplementary figure 1) were 
reduced, while the neutral amino acid transporter SLC1A5, responsible for the transport of 
glutamine into tumour cells, was significantly increased (Figure 3.2.1), suggesting MB 
tumours may prefer de novo glutamate synthesis rather than exogenous uptake. 
Furthermore, the expression of these transporters proved to be prognostic, with low EAAT1 
and high SLC1A5 being predictive of a worse overall survival in MB patients (Figure 3.2.1). 
We also investigated genes more directly involved in glutamine catabolism (GLS1, GLS2 and 
GLUD1) and anabolism (GLUL).  GLS1 expression was highest in the SHH-MB subgroup when 
compared to the other three conventional groups, although, when compared to normal 
cerebellum (CB) we found increased expression in all MB tumour types (Figure 3.2.1). We 
observed GLS2 expression was highest in Grp4 MB, but no differences were observed when 
compared to CB. GLUD1, which allows the NAD(P)+ dependent release of the amino group 
of glutamate to form αKG, is an important enzyme which contributes towards TCA 
anaplerosis. Our results revealed a striking and significant alteration in GLUD1 expression, 
where its expression in decreased in the SHH, Grp3 and Grp MB subgroups, which have a 
more aggressive phenotype than the WNT group (Cavalli et al., 2017). We also observed 
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decreased expression in MB tumours compared to CB, which interestingly held up as  
prognostic in patients, with low expressing patients having a significantly poorer overall 
survival (OS) compared to their higher GLUD1 expressing counterparts (Figure 3.2.1). 
Glutamine synthetase (GLUL) is an ATP-dependent enzyme which catalyses the 
condensation of ammonium to glutamate, forming glutamine. In many cancers, the intricate 
balance equilibrium between glutamine anabolism and catabolism is vital. We therefore, 
investigated GLUL in MB and showed no significant changes in expression when compared 
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3.2.2 Increased glutamine catabolism over glutamine anabolism predicts survival in MB 
patients. 
 
To determine the importance of glutamine catabolism or anabolism in MB tumours, we also 
analysed survival data from a publically available GEO data set (GDS4471). When using a 
median expression cut off value, a correlation was found between overall survival of MB 
patients and expression of GLS1, where increased expression significantly decreased 
survival. Moreover, we observed a strong trend with GLUL expression, with low expressing 
patients having a poorer overall survival. To further elucidate this, we utilised gene 
expression ratios GLS1:GLUL and (GLS1+GLUD1)/GLUL, which give a read out of glutamine 
catabolism versus anabolism and is generally considered as a valid representation of such 
(Yang et al., 2014). We establish that opposing activities of glutamine catabolism and 
glutamine anabolism, in our dataset, act as a biomarker for predicting survival in MB 
patients. We found that patients with high GLS1/GLUL and (GLS1 + GLUD1)/GLUL ratios had 
significantly poorer prognoses than patients with lower ratios (Figure 3.2.2). These data 
were further strengthened through proteomic analysis of the GLS: GLUL in MB tumours 
(Figure 3.2.3).  
 
 
Figure 3.2.1. Expression of glutamine-related genes was associated with survival in MB 
tumours.  A) RNA expression data compared across subgroups of MB and representative Kaplan-
Meier survival curves of the MB Newcastle cohort. n=240 (WNT n=28, SHH n=58, G3 n=59 and 
G4 n =95). High and low expression was determined by the median expression value for each 
gene. Log-rank (Mantel-Cox) statistical test was performed in Kaplan-Meier survival graphs. 
Unpaired two-tailed t-test statistical tests were performed in mRNA expression data graphs; 
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Figure 3.2.2. Kaplan-Meier of GLS1 / GLUL mRNA ratio is associated with survival in 
MB patients. Analysis of GLS1/ GLUL mRNA ratio reveals increased glutamine 
catabolism is associated with a worse overall survival. Clinical and mRNA expression 
data, from MB patients, was extracted from an online NCBI Geo repository (accession 
number: GDS4471). This Expression profiling array, included 76 samples, each 
belonging to the separate MB subgroups; WNT (n=8), SHH (n=11), G3 (n=16) and G4 
(n=39).  High and low expression was determined by the median expression value for 
each gene. Log-rank (Mantel-Cox) statistical test was performed in Kaplan-Meier 
survival graphs. Unpaired two-tailed t-test statistical tests were performed in mRNA 















3.2.3. Glutaminase expression in MB cell lines. 
 
To investigate the expression of GLS isozymes in the model cell lines, DAOY, UW228.3 and 
ONS-76, a quantitative real-time PCR analysis was performed. Significant differences in the 
expression of these enzymes were observed between the cell lines, with ONS-76 exhibiting 
the lowest GLS1 but highest GLS2 expression, and UW228.3 with the highest GLS1 but 
lowest GLS2 expression (figure 3.2.4 B). Having acquired mRNA expression of GLS1 and GLS2 
in the MB cell lines, we further explored these enzymes by means of protein expression by 
immunoblot analysis (figure 3.2.4 A). GLS1 protein expression was similar across all cells 
lines, differing only in the DAOY cells. Furthermore, we observed several protein bands for 
GLS1, which we believe two of the bands to be specific towards the two splice variants (KGA 
and GAC), due to their reduced expression upon RNA knockdown with siGLS1 
(Supplementary figure 2). GLS2 protein expression however, was only observed in the ONS-
Low GLS1: GLUL 
High GLS1: GLUL 
Figure 3.2.3. Kaplan-Meier of GLS1 / GLUL protein ratio associated 3 years survival. 
Proteomic analysis of GLS1/ GLUL ratio reveals increased glutamine catabolism is 
associate with a worse overall survival. High (n=9) and low (n=27) groups were 
determined by Last quartile (log10-ratio>1, 5). * p=0.045. Data generated by Ayrault 






76 and DAOY cell lines, with ONS-76 expressing the greatest amount. Overall, GLS2 protein 








Figure 3.2.4. Glutaminases are differentially expressed between MB cell lines. A) 
Immunoblot analysis of GLS1 and GLS2 show different protein expression between 
ONS-76, DAOY and UW228.3 cell lines. Actin was used as a loading control. B) 
Densitometry values from immunoblot. C) Glutaminase mRNA expression was 

















































































3.2.4 MB cell lines are addicted to glutamine.  
 
To understand glutamine dependence in MB cells, we first analysed cell proliferation, by 
means of an SRB growth assay, of three MB cell lines (ONS-76, DAOY and UW228.3) under 
complete medium (2mM glutamine) and varying degrees of glutamine deprived conditions 
(0-1mM). All three cell lines show a dependency on glutamine to sustain optimal growth, 
with complete glutamine deprivation leading to reduced growth in the ONS-76 and 
UW228.3 (Figure 3.2.5 A and C) cell lines and cell death after 24h in the DAOY line (Figure 
3.2.5 B). Our data therefore demonstrate a reliance on glutamine in the MB cell lines tested. 
The structure of glutamate is similar to that of glutamine, lacking only an amide group. We 
investigated whether the addition of a methylated form of glutamate, N-Methyl-L-glutamic 
acid, which efficiently delivers glutamate into cell, could rescue growth in cell lines cultured 
in 0mM glutamine. Our results conclude that N-Methyl-L-glutamic acid is unable to rescue 
growth, suggesting an importance for de novo glutamate synthesis from gln (Figure 3.2.5 D). 
In parallel, we also observed a requirement for exogenous glucose in all three cell lines 

















Figure 3.2.5. MB cell lines require glutamine for growth. A-C) SRB growth curves of ONS-76, 
DAOY, and UW228.3 cell lines incubated with 0, 0.5, 1 or 2mM glutamine for 3 days (72 h). 
Incubation in 0mM glutamine significantly decreased the growth rate of all three cell lines, 
with the DAOY cell line showing heightened reliance on glutamine. D) SRB relative growth of 
MB cell lines incubated with 0mM glutamine, 0mM glutamine + 2mM methyl-glutamate or 
0mM glucose. Glutamate is unable to rescue growth in 0mM glutamine conditions. Glucose is 
vital for MB cell line growth. Data shown as mean ±SEM, representative of 3 independent 
experiments and analysed with an unpaired t-test; *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
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3.2.5 MB cell lines show increased glutamine catabolism and low glutamine anabolism 
 
To further understand the importance of glutamine, we explored the relative use of 
glutamine catabolism versus its anabolism within our three cell lines, by measuring the 
incorporation of 13C-U-glutamine into glutamate (representative of GLS activity), alpha-
ketoglutarate (representative of GLUD and transaminase activity) and back into glutamine 
(representative of GLUL activity). In the presence of 13C-U-glutamine for 24h we observe 
high m+5 labelling into both glutamate and alpha-ketoglutarate (Figure 3.2.6), suggesting a 
high flux of glutamine catabolism into these downstream metabolites.  
Two carbons of glucose are commonly utilised in the synthesis of glutamine, however, no 
m+2 label incorporation into glutamine was observed when cells where fed with 13C-U-
glucose (Figure 3.2.7 A), which suggest a lack glutamine synthetase activity. Furthermore, 
we observed minimal levels of m+1, m+2, m+3 and m+4 isotopologues of glutamine from 
13C-U-glutamine in the ONS-76 cell line (Figure 3.2.7 A), suggesting partial GLUL activity in 
these cells. However, labelling with 13C-U-glutamine reveals only the recycling of the carbon 
backbone, of which glutamine, glutamate and αKG share identical carbons. These 
metabolites alter in their nitrogen composition, with the deamidation of glutamine resulting 
in a loss of the amide nitrogen, and a loss of the amine nitrogen when glutamate is 
deaminated to αKG. We therefore labelled with 13C5, 
15N2-glutamine to better appreciate 
GLUL activity. Our data further support a lack of GLUL activity with low m+6 and no m+5 
labelled glutamine observed (Figure 3.2.7 C). Taken together, these results are indicative of 
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Figure 3.2.6. MB cell lines undergo glutamine catabolism. Analysis of the mass 
isotopomer distribution (MID) of glutamine- derived metabolites. A) Glutamine catabolism 
can be assessed through MID analysis of downstream metabolite; glutamate (via GLS 
activity), α-KG (via GLUD1 activity) and malate (indicative of TCA cycle metabolism). B) 
Extensive 13C label incorporation is observed in glutamine-derived metabolites after 24 h 
incubation with 13C-U-glutamine. Data is performed in technical triplicate, mean +/- S.D. 
Statistical significance determined using two-tailed unpaired Student’s t-test; *p<0.05, 
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Figure 3.2.7. Low glutamine synthase activity in MB cells. Analysis of the mass isotopomer 
distribution (MID) of glutamine to assess GLUL activity. Mass isotopologues (m+0, m+1, m+2, 
m+3, m+4 and m+5) correspond to ion fragments containing different 13C atoms. A) No 13C 
label incorporation is observed in glutamine after 24 h incubation with 13C-U-glucose, 
suggesting no glucose-derived glutamine via GLUL activity. B) Glutamine-derived metabolites 
can be converted back to glutamine through GLUL activity. Minute 13C label incorporation is 
observed in glutamine after 24 h incubation with 13C-U-glutamine, suggestive low GLUL 
activity. Data is performed in technical triplicate; mean +/- S.D. Statistical significance 














3.2.6 GLS1 is the primary functioning glutaminase  
 
The conversion of glutamine to glutamate is predominantly catalysed through glutaminase 
enzymes, of which two isoforms exist- GLS1 and GLS2. We previously identified GLS1 as 
being highly expressed in our cell lines, while GLS2 expression was low in the ONS-76 and 
DAOY cell line and no expression was observed in the UW228.3 line (Figure 3.2.4). We 
further investigated the relative activities of these two isoforms by knocking-down either 
GLS1 or GLS2 in the MB cell line models. Knock-down was achieved using short interfering 
RNA (siRNA), attaining significant reduction in mRNA of both GLS1 splice variants; KGA and 
GAC and protein expression, and a reduction in GLS2 protein and mRNA (Supplementary 
figure 2). To investigate the metabolic changes accompanying GLS1 knockdown, the mass 
isotope distribution (MID) of metabolites after incubation with uniformly-labelled-13C 
glutamine (13C5-U-glutamine) was measured. Upon GLS1 KD, the m+5 isotopologue of 
glutamate (which represents a read-out of the direct synthesis of glutamate from 
glutamine) was significantly decreased, consistent with reduced GLS1 activity. We observed 
no changes in label incorporation into glutamate upon GLS2 knock-down, suggesting our cell 
lines do not utilise this isoform of GLS under basal conditions. Furthermore, siGLS1 but not 
siGLS2 significantly reduced the growth of all three cell lines (Figure 3.2.8 B), further 
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Figure 3.2.8. GLS1 is the actively used glutaminase in MB. Analysis of the mass 
isotopologue distribution (MID) of glutamine- derived glutamate. A) Significant reductions 
in 13C label incorporation is observed in siGLS1 treated MB cell lines after 24 h incubation 
with 13C-U-glutamine compared to siNT and siGLS2, suggestive of favoured GLS1 activity. B) 
Relative growth curves of ONS-76, DAOY, and UW228.3 cell lines incubated with siNT, 
siGLS1 or siGLS2 for 3 days (72 h). Treatment with siGLS1, but not siGLS2 significantly 
decreased the growth rate of all three cell lines. Data is performed in technical triplicate, 
mean +/- S.D. Statistical significance determined using two-tailed unpaired Student’s t-























3.2.7 Reduced glutamate impairs oxygen consumption 
 
Our observations that decreased glutamate synthesis reduces MB cell line growth led us to 
hypothesise that glutamate may be important for TCA cycle metabolism, where mitochondrial 
respiration is a key element of cell growth. To understand the contribution of glutamate to 
mitochondrial respiration, we performed a high-resolution respirometry assays using 
OXPHOS modulators in intact MB cells treated with DMSO or BPTES (a GlS1 inhibitor). 
Treatment with BPTES significantly reduced the Routine oxygen consumption of all three 
cell lines (Figure 3.2.9), suggesting an important role for glutamate in maintaining OXPHOS 
under basal conditions. In order to evaluate the dependence of respiratory complexes on 
oxygen consumption (OC), we used membrane permeable compounds that affect 
















































































































































































































Subsequently, we measured the ‘leak’ OC (ATP synthase-independent respiration in the 
presence of oligomycin). Our results show that BPTES treatment has no impact on leak OC, 
suggesting glutamate is not used in mitochondrial-independent OC. We further measured 
the maximal oxygen consumption rates (ETS) through FCCP uncoupling and show 
significantly decreased OC with BPTES treatment. Routine/leak represents the OC attributed 
to electron transport chain (mitochondrial) activity only, where our results demonstrate that 























Figure 3.2.10. GLS1 splice variants, KGA and GAC expression and localisation differences. A) 
Immunoblot analysis of KGA and GAC protein in the ONS-76, DAOY and UW228.3 cell lines. B) 
Quantification of immunoblot by densitometry analysis. C) Immunoblot analysis of fractionated 
(mitochondrial and cytosolic) MB cell lines. LDH (lactate dehydrogenase) was used as a cytoplasmic 















































Figure 3.2.9. Glutamate promotes mitochondrial metabolism in MB. A) Bar graph representing the 
results of the various states measured with high-resolution respirometry (error bars ± SEM of 3 
independent experiments). B) Mode of action for BPTES. Treatment with BPTES reduces glutamine-
derived glutamate to the same extent as siGLS1. 
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3.2.8 Relative expression and localisation of the GLS1 splice variants  
 
GLS1 is typically referred to as a mitochondrial enzyme. However, more recently it has been 
shown to also exist in the cytosol, with the two splice variants, KGA and GAC, being 
differentially restricted to each compartment – the former to the cytosol and the latter, the 
mitochondria. The relative expressions of the KGA and GAC splice variants have not 
previously been identified in the setting of MB. We therefore investigated the expression 
and localisation of each isozyme in the MB cell lines, and observed that although both 
variants were expressed, GAC appeared to be the major isoform in the DAOY and UW228.3 
cell lines, while no differences were observed in the ONS-76 line (Figure 3.2.10 A and B). In 
order to investigate whether the variants were differentially localised, mitochondrial and 
cytosolic (including nuclear) fractions were generated and immunoblotted as before. It was 
found that, consistent with the literature on other cancer types (Cassago et al., 2012), KGA 
localised mainly to the cytosol, while GAC was predominantly mitochondrial, although some 
expression was observed in the cytosolic fraction of the DAOY cell line (Figure 3.2.10 C).  
To investigate the importance of these enzymes in MB biology, we measured the effect of 
GAC and KGA knockdowns (Figure 3.2.11) on relative growth in two of our cell lines, ONS-76 
and DAOY. Our results highlight differences in dependencies of cells on each splice variant, 
with siGAC resulting the largest reduction in growth (figure 3.2.12), suggesting MB cell lines 
prefer the GAC isoform to sustain growth. To further understand their relative importance, 
we examined the metabolic changes accompanying KGA or GAC knockdown, through mass 
isotope distribution (MID) analysis, using 13C fully labelled glutamine (13C5-U-glutamine). 
Upon knockdown of either GAC or KGA, the m+5 isotopologue of glutamate was significantly 
decreased (Figure 3.2.13), consistent with reduced GLS1 activity observed with siGLS1. Our 
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results reveal siGAC decreased label incorporation to a larger extent than with siKGA, 
suggesting increased GAC activity compared to KGA. The same is apparent for αKG and key 
TCA intermediates: succinate and malate and in oxidative-derived citrate (m+1 to m+4). We 
observed no additional effect on m+5 citrate (reductive-derived) when siGAC is compared 
with siKGA, suggesting an additional impact of KGA when citrate is made in the cytosol, or 
















































































































































































































Figure 3.2.11. Successful knock down of GLS1 splice variants. Successful knock down of GLS1 
variants KGA and GAC protein was validated for all experimental conditions. A) Immunoblotting 
demonstrates protein knock down of KGA and GAC by two independent siRNA transcripts 24 and 
48 h post transfection. B) Densitometry analysis of KGA knockdown immunoblot. C) qPCR 
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Figure 3.2.12. The effect of GLS1 splice variants, KGA and GAC on MB growth. Relative growth 
curves of ONS-76, DAOY, and UW228.3 cell lines incubated with siNT, siKGA or siGAC for 3 days 
(72 h). Treatment with siKGA and siGAC significantly decreased the growth rate of all three cell 
lines, compared to siNT control, with siGAC showing the largest reduction in growth. Data is 
performed in technical triplicate with 3 independent experiments, mean +/- S.D. Data analysed 









Figure 3.2.13. GAC activity is preferred in MB. Analysis of the mass isotopologue distribution 
(MID) of glutamine- derived glutamate. A) Significant reductions in 13C label incorporation is 
observed in siGLS1 treated ONS-76 line after 24 h incubation with 13C-U-glutamine compared 
to siNT and siGLS2, suggestive of favoured GLS1 activity. Data is performed in technical 
triplicate, mean +/- S.D. Statistical significance determined using two-tailed unpaired Student’s 




3.2.9 Glucose metabolism is increased after GLS1 knock-down. 
 
Glucose and glutamine are major anabolic carbon sources in most tumours, with our results 
suggesting they both have important roles in MB cell growth. There is evidence to suggest 
that loss of one carbon source can be somewhat compensated by enhanced metabolism of 
the other. However, it has also been shown that glucose metabolism may be negatively 
impacted upon glutaminase inhibition (Pan et al., 2015). We utilised both 13C-U-glucose and 
13C-U-glutamine to investigate the metabolic alterations induced by GLS inhibition in the MB 
cell lines.  Upon entry of pyruvate into the mitochondria, there are two means of entry to 
the TCA cycle; the oxidative decarboxylation of pyruvate to acetyl CoA by PDH, and 
carboxylation of pyruvate by PC forming oxaloacetate as a result. Both of these pathways 
may yield αKG and subsequently glutamate via further TCA metabolism. The unique MIDs 
produced from 13C-U-glucose can reveal the relative activities of PDH (m+2 citrate) and PC 
(m+3 citrate) (Figure 3.2.14 A). We therefore incubated MB cells with siGLS1 with 13C6-U-
glucose, and found that m+2 and m+3 glutamate isotopologues were increased compared to 
control conditions, suggestive of relatively increased glucose-derived glutamate synthesis, 
via PDH and PC activity, respectively. We also noted significant increases in m+4 and m+5, 
indicating further TCA cycle activity resulting in glutamate synthesis (figure 3.2.14 B). 
Glucose contribution towards glutamate biosynthesis was shown to almost double after 
siGLS1, suggesting increased glucose metabolism is utilised in an attempt to compensate for 
reduced glutamate and therefore highlighting the importance of glutamate synthesis in MB 
cell lines (figure 3.2.14 C). However, glutamate concentrations were not rescued by 
heightened glucose metabolism (Figure 3.2.14 D).  
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We subsequently measured the different contributions of glutamine and glucose towards 
the biosynthesis of glutamate in all three MB cell lines. Through the use of both 13C tracer 
metabolites, we were able to establish the total carbon contribution of glucose and 
glutamine towards glutamate synthesis. Unsurprisingly, we found around 50% of glutamate 
was derived from glutamine in the ONS-76 cell lines, 60% observed in the UW228.3 line and 
a contribution of 80% in the DAOY cell line, highlighting the differential dependencies on 
glutamine between our MB cell lines (figure 3.2.15 C). Furthermore, our results show a 
smaller contribution of glucose towards glutamate synthesis, with 15%, 5% and 18% 
observed in the ONS-76, DAOY and UW228.3 lines respectively (figure 3.2.15 C).  
Figure 3.2.14. Glucose attempts to rescue glutamate concentrations when GLS1 
activity is impaired, through increased pyruvate carboxylase activity. A) M+5 
Incorporation of [U-13C5]-glutamine into glutamate is decreased upon KD of GLS1. B) 
[U-13C5]- glucose incorporation into glutamate is increase upon KD of GLS1. C) Despite 
increased contribution of glucose to glutamate; steady state levels show an inability of 































































































































































3.2.10 Glutamate is exported from MB cell lines.  
 
We have shown that MB cell lines demonstrated high glutamine use, and that neither 
glutamate feeding, nor enhanced glucose metabolism could compensate in glutamine-
depleted conditions. As glutamate concentrations were previously shown to negatively 
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Figure 3.2.15. Utilisation of glucose in MB cell lines. A) Label incorporation of glucose into 
downstream metabolites. B) Analysis of the mass isotopologue distribution (MID) of 
glucose- derived metabolites. C) Total carbon contribution of glucose and glutamine 
towards glutamate synthesis. (n=3) 
ONS-76 DAOY UW228.3 
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concentrations of glutamate in MB cell lines and their environment. This is particularly 
important, as the patient study was unable to define whether the glutamate levels 
measured were cellular or stromal. We show that although intracellular concentrations of 
glutamate are consistently in the low micromolar range (Figure 3.2.16 B), extracellular 
concentrations of glutamate were relatively high, especially so in the DAOY cell line, given 
that the medium contained no exogenous glutamate (Figure 3.2.16 C). To examine the 
source from which the glutamate was synthesised by cells, we cultured them in the 
presence of stable isotope-labelled 13C-U-glutamine, and monitored the synthesis and 
excretion of 13C-labelled glutamate. We found that at least 50% of the extracellular 
glutamate was labelled from glutamine – with over 75% observed in the DAOY cell line 
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3.2.11 SLC7A11 is expressed in MB, which pairs glutamate export with cystine import. 
 
Glutamate export has been implicated in glioma cell growth and invasion (Takano et al., 
2001), with an important role for the glutamate/cystine transporter SLC7A11 (XCT) being 
reported (Polewski et al., 2016). However, the role of SLC7A11 has not been previously 
shown in MB. We demonstrate SLC7A11 protein expression in both MB tumours (Figure 
3.2.17 A) and cell lines (Figure 3.2.17 C), suggesting a role for this anti-porter in MB biology. 
To further assess the importance of SLC7A11 in the MB cell lines, we inhibited this system 
using sulfasalazine, SSZ – a well-described inhibitor of this transporter. After treatment, we 
observed decreased intracellular concentrations of cysteine (Figure 3.2.17 D), consistent 
with reduced SLC7A11 activity. We also found that SSZ treatment reduced cell growth in all 
three lines (Figure 3.2.17 E), suggesting that interfering with glutamate/cystine transport 
may be beneficial in the treatment of MB tumours. Importantly, this effect was abolished by 
the addition of the reducing agent, 2-mercaptoethanol (2-ME) to cells, which facilitates the 
uptake of cystine independently of the xCT transporter by reducing cystine to cysteine, 
allowing its uptake through an alternative transporter.  
 
 
Figure 3.2.16. Assessing intracellular and extracellular glutamate concentrations. A) 
Glutamate concentration curve was generated using calibration series of glutamate 
standards by GC-MS. B) Cellular glutamate concentrations in the ONS-76, DAOY and 
UW228.3 cell lines. C) Extracellular (media) glutamate concentrations reveal extensive 
glutamate release in the DAOY cell line. D) MID analysis of extracellular glutamate after 24 




























































































































































































Figure 3.2.17. The glutamate/cystine antiporter, SLC7A11 is expressed in MB 
tumours and cell lines. A) Immunohistochemical analysis of SLC7A11 expression 
in MB tumours. Colon tissue was used as a positive control for SLC7A11 staining 
and Lung tissue was used as a negative control. B) Treatment with Sulfasalazine 
(SSZ) inhibits SLC7A11 activity. C) SLC7A11 expression in MB cell lines. D) 
Decreased cysteine ion count after SSZ treatment. (n=3) E) Relative growth of MB 
cell lines treated with 2-ME, SSZ or 2-ME + SSZ compared to DMSO control. (n=3) 
* * * 
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3.2.12 Genes encoding proline biosynthesis predict survival in MB patients 
 
Our results highlight the importance of glutamate, separate to its function in feeding the 
TCA cycle. We therefore explored other avenues in which glutamate may exert its effects. 
One of the many metabolic pathways in which glutamate plays a role is in the synthesis of 
proline, which has recently been highlighted as an important pathway in some cancers 
(Phang et al., 2015). We therefore assessed the expression of several proline-related 
metabolic genes and the result of this on patient survival, using two independent databases 
(Newcastle cohort and online database, GEO: GSE42658). We noted that in all cases, 
expression of the proline biosynthetic genes (ALDH18A1, PYCR1 and PYCR2) were increased, 
while PRODH, responsible for the breakdown of proline, was significantly decreased (Figure 
3.2.18). Furthermore, the expression of these genes proved to be prognostic, with high 
ALDH18A1 and PYCR1, and low PRODH being predictive of a worse overall survival in MB 
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GEO: GSE42658 
Figure 3.2.18. Expression of proline metabolic-related genes was associated with 
survival in MB tumours.  A) RNA expression data compared across subgroups of MB and 
Representative Kaplan-Meier survival curves of the MB Newcastle cohort. n=240 (WNT 
n=28, SHH n=58, G3 n=59 and G4 n =95). High and low expression was determined by the 
median expression value for each gene. Log-rank (Mantel-Cox) statistical test was 
performed in Kaplan-Meier survival graphs. Unpaired two-tailed t-test statistical tests 





3.2.13 Proline biosynthesis in MB cell lines 
 
After establishing an important correlation of proline-related genes expression in MB 
tumours with patient outcomes, we investigated the role of proline metabolism further in 
the MB cell lines. As proline metabolism activity can be dictated by expression of related 
enzymes, we measured the relative expression of: pyrroline-5-carboxylate synthetase 
(ALDH18A1), pyrroline carboxylate reductase 1 (PYCR1) and 2 (PYCR2) (Figure 3.2.19 A) 
between cell lines. Enzyme expression was observed in all of our lines, where ONS-76 had 
relatively higher expression of all three enzymes (Figure 3.2.19 B), as confirmed by 
densitometry analysis (Figure 3.2.19 C). Although indicative, protein expression does not 
fully reveal metabolic pathway activities. We therefore, investigated the extent of proline 
biosynthesis by means of 13C-U-glutamine incorporation into proline. Our results suggest 
A 
B 
Figure 3.2.19. MB cell lines express proline biosynthetic enzymes. A) Enzymes involved in the 
biosynthesis of proline. B) Protein expression of enzymes involved in proline metabolism, in MB 
cell lines. Gene expression of enzymes involved in the biosynthetic pathway. Experiments 
performed in technical and biological triplicate. Data is mean +/- S.E.M. Significance 




heightened glutamine-derived proline biosynthesis in our cell lines, with up to 50% label 
incorporation observed after 24 h (Figure 4.2.20).  
 
3.2.14 Proline biosynthesis helps control intracellular glutamate  
 
Another source of proline is through the metabolism of arginine. Arginine can be hydrolysed 
by ARG1 to ornithine, which subsequently may be converted to proline through ornithine 
aminotransferase (OAT) activity. As the most abundant amino acid in brain tissue, arginine, 
or arginine-derived ornithine may also be used in proline biosynthesis in MB cells. To 
investigate this, we used a competition assay between arginine and 13C-U-glutamine or 
ornithine and 13C-U-glutamine, where we would expect 13C label incorporation into proline 
to decrease if the competing metabolite is used to synthesise proline. Surprisingly, we find 
no change between arginine addition and control (Figure 3.2.21 A), suggesting this 
metabolite is not used in proline biosynthesis. However, we observe a significant decline in 
labelled proline when ornithine was added to the medium (Figure 3.2.21 B), indicating a 
strong role of ornithine in proline biosynthesis. Our data also reveals an increase in 
glutamate ions upon ornithine addition (Figure 3.2.21 C), suggesting that in the absence of 












































































































































Figure 3.2.20. Glutamine- derived proline synthesis in MB. Analysis of the mass 
isotopologue distribution (MID) of glutamine- derived proline. (n=3) 
NS-76 DAOY W228.3 
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(Figure 3.2.21 D), possibly suggesting that ornithine and glutamate contribute equally to 
proline synthesis, when ornithine concentrations are present. It is surprising to observe 
differences between arginine and ornithine, given that they are so closely interrelated. We 
therefore hypothesised that there must be a reduced potential of our cell lines to synthesise 
ornithine from arginine, through ARG1. We investigated the expression of ARG1 in MB 
tumours and observed reduced ARG1 RNA compared to CB control (Figure 3.2.22). Our data 
suggest proline synthesis from arginine is reduced in preference for glutamate as the 
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Figure 3.2.22. Expression of proline-related genes was associated with survival in MB 
tumours.  A) Representative Kaplan-Meier survival curves of the online NCBI Geo 
repository cohort (accession number: GDS4471). This Expression profiling array, 
included 76 samples, each belonging to the separate MB subgroups; WNT (n=8), SHH 
(n=11), G3 (n=16) and G4 (n=39). High and low expression was determined by the 
median expression value for each gene. Log-rank (Mantel-Cox) statistical test was 
performed in Kaplan-Meier survival graphs. Unpaired two-tailed t-test statistical tests 
were performed in mRNA expression data graphs ; *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
 
Figure 3.2.21. Ornithine increases glutamate concentrations by relieving glutamate 
driven proline synthesis. Proline biosynthesis from arginine/ornithine or glutamate. 
A) Glutamine-derived glutamate does not alter with exogenous arginine or ornithine. 
B) Glutamate-derived proline is reduced with exogenous ornithine. C) Glutamate ions 
increase with ornithine treatment. D) Proline ion count is unaffected by ornithine 
and arginine treatment. Data is performed in technical triplicate, mean +/- S.D. 
Statistical significance determined using two-tailed unpaired Student’s t-test; 




3.2. 15 Proline is exported from MB cell lines  
 
Analysis of the culture media revealed glutamine-derived proline is exported from MB cell 
lines (Figure 3.2.23), suggesting concentrations of proline exceed metabolic demand. Within 
the microenvironment, proline is essential in the formation of collagen. Research has also 
revealed a potential role of type one collagen in MB tumours (Liang et al., 2008). To 
investigate this further, a Van Gieson’s stain was used to assess collagen in MB tumours. 
Immunohistochemical analysis revealed extensive collagenous networks compared to CB 




































































































































































































Figure 3.2.23. Proline is exported from MB cells. Analysis of the mass isotopologue 
distribution (MID) of glutamine- derived proline in the media of cell lines incubated with 13C-
U-glutamine for 24 h. (n=3) 



















3.2.16 Exogenous proline decreases MB cell line growth. 
 
It has been previously reported that exogenous proline can regulate its intracellular 
biosynthesis, via inhibition of PYCR1/2 (de Ingeniis et al., 2012; Liu et al., 2015). This 
sensitivity of PYCR to product inhibition led us to investigate whether increasing 
extracellular proline concentrations (0, 200 and 400 µM) would have a similar effect in the 
MB cell lines. In order to investigate this, we measured 13C incorporation into proline from 
glutamine (13C-U-glutamine) when cells were cultured with 0, 200 or 400µM exogenous 






















Figure 3.2.24. Histologic illustration of collagen in normal cerebellum (CB) 
and MB. A Van Geison stain was used to assess the extent of collagen 
deposits in MB tumours. MB tumour shows increased deposits of collagen 
compared to CB control tissue, demonstrated by the pink fibres.  
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reduced glutamine-derived proline (Figure 3.2.25). We further show that exogenous proline 
resulted in decreased growth in all three cell lines, in a concentration dependent manner, 
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Figure 3.2.25. Exogenous proline reduces glutamine-derived proline. The mass isotopologue 
distribution (MID) of proline is reduced when cells are cultured in medium containing 200µM 

























3.2.17 Genes involved in GABA metabolism are predictive of survival in MB patients 
 
Glutamate plays a significant role in neurotransmission, both directly as an excitatory 
neurotransmitter and indirectly through the synthesis of the inhibitory neurotransmitter, 
GABA. We therefore investigated the expression of several GABA-related metabolic genes in 
MB tumours. We observed decreased expression of the main biosynthetic gene, GAD1 when 
compared to CB, suggesting decreased de novo synthesis of GABA in MB tumours (Figure 
3.2.27). Furthermore, the expression of GAD1 proved to be prognostic, with high expressing 
patients having a lower overall survival compared to their low GAD1 expressing 
counterparts. These results suggest GABA biosynthesis is reduced in MB tumours. Further 
mRNA expression analysis revealed additional disruption of genes involved in GABA 
Figure 3.2.26. Exogenous proline reduces MB cell line growth. MB cell line growth is reduced when 
cells are cultured in medium containing 200 or 400µM proline. . A) Reduced growth was determined 
by light microscopy. B) Growth was further assessed by an SRB proliferation assay. Data is performed 
in technical triplicate with 3 independent experiments, mean +/- S.D. Data analysed with an unpaired 



































































































































metabolism, with the major transporter involved in GABA uptake, SLC6A1 and the 
GABAergic receptor, GABRA2 both being downregulated in MB tumours compared to CB 
control tissue. These findings further strengthen the fact that MB tumours favour low GABA 
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Figure 3.2.27. Expression of GABA-related genes was associated with survival in MB tumours.  A) 
RNA expression data compared across subgroups of MB and representative Kaplan-Meier survival 
curves of the MB Newcastle cohort. n=240 (WNT n=28, SHH n=58, G3 n=59 and G4 n =95). High 
and low expression was determined by the median expression value for each gene. Log-rank 
(Mantel-Cox) statistical test was performed in Kaplan-Meier survival graphs. Unpaired two-tailed t-






















3.2.18 MB cell lines block GABA biosynthesis 
 
GABA is synthesised from glutamate via GAD enzyme activity (Figure 3.2.28 A). We 
investigated the extent of glutamine-derived GABA biosynthesis in our MB cell lines, by 
means of measuring 13C-U-glutamine incorporation into GABA. Our results suggest a block in 
glutamine-derived GABA biosynthesis in our cell lines, with only slight m+1 label 
incorporation observed after 24 h (Figure 3.2.28 B). Our results align with our previous 
























































































































































































































































































































































































































Figure 3.2.28. De novo GABA biosynthesis is abolished in MB cell lines. A) Glutamate is a 
direct precursor for de novo GABA synthesis. B) No 13C label incorporation into GABA when 








































3.2.19 Exogenous GABA reduces growth in the UW228.3 cell line. 
 
We would predict that MB cells have reduced GABAergic properties, due to the reduced 
receptor expression observed in tumours. We therefore incubated all three cell lines with 
exogenous concentrations of GABA (0, 200 and 400 µM) to investigate this further. Indeed, 
we see no changes in cell growth in the ONS-76 and DAOY cell lines, although, exogenous 
GABA reduces growth in the UW228.3 cell lines (Figure 3.2.29), suggesting an ability of these 
cells to react to GABA. 
 
Figure 3.2.29. Exogenous GABA reduces growth in the UW228.3 cell line. UW228.3 cell line growth is 
reduced when cells are cultured in medium containing 200 or 400µM GABA. A) Reduced growth was 
determined by light microscopy. B) Growth was further assessed by an SRB proliferation assay. Data is 
performed in technical triplicate with 3 independent experiments, mean +/- S.D. Data analysed with an 

























3.3.1 Introduction  
 
The metabolism of two major energy sources, glucose and fatty acids have previously been 
well described in MB (Gershon et al. 2013; Tech et al. 2015). It was not until more recently, 
however, that a significant role for glutamine metabolism has been shown in these tumours 
(Niklison-Chirou et al., 2017), with glutamate concentration also being identified as a 
prognostic marker in MB patients (Wilson et al., 2014). These data highlight the potential 
role of glutamine and glutamate in MB tumours, although not surprising given that 
glutamine metabolism has been shown as critical for normal tumour function in many 
different tumour types (Daye and Wellen, 2012). Furthermore, as a number of therapies are 
being trialled toward targeting glutamine metabolism, it is important to understand how its 
metabolism may be altered specifically in MB. 
3.3.2 Genes involved with glutamine metabolism are altered in MB patient tumours. 
 
The data presented investigate for the first time the expression of metabolic genes and their 
clinical consequences in MB patients. We noted that in all cases, expression of the 
glutamate uptake transporters EAAT1 (Figure 3.2.1) and EAAT2-4 (supplementary Figure 1) 
were reduced, while the neutral amino acid transporter SLC1A5, responsible for the 
transport of glutamine into tumour cells, was significantly increased. Furthermore, the 
expression of these transporters proved to be prognostic, with low EAAT1 and high SLC1A5 
being predictive of a worse overall survival in MB patients (Figure 3.2.1). It has been 
previously shown that EAAT-2 expression is decreased in high-grade glial tumours when 
compared with normal brain or even low-grade astrocytomas (de Groot et al., 2005). The 
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same group also revealed that EAAT-2 expression was inversely correlated with tumour 
grade. It is interesting therefore that we observed reduced EAAT expression in MB. Although 
we see reduced expression of EAAT-2, this does not correlate with survival in patients and 
only EAAT-1 and EAAT-3 expression affected clinical outcomes. It is no surprise that we 
observe heightened SLC1A5 expression as tumours typically favour glutamine uptake. 
SLC1A5 has been shown to be overexpressed in several tumours including, prostate (Carr et 
al., 2010), colorectal (Huang, Zhao, et al., 2014), aggressive subtypes of breast cancer (Kim 
et al., 2013) and gliomas (Vastrad and Vastrad, 2018). Our data suggests that MB tumours 
prioritise glutamine uptake and subsequently utilise de novo glutamate synthesis rather 
than exogenous uptake. 
We also investigated genes involved in glutamine catabolism (GLS1, GLS2 and GLUD1) and 
anabolism (GLUL) in MB tumours.  GLS1 expression was highest in the SHH-MB subgroup 
when compared to the other three conventional groups, although when compared to 
normal cerebellum (CB) no expression differences were observed. Previous studies in 
colorectal tumours (Huang, Zhang, et al., 2014) have shown increased expression of GLS1 in 
tumours compared to normal tissue, suggesting a role for GLS1 in cancer progression.  
Increased glutamine transporter expression and high glutamate concentrations reported in 
vivo (Wilson et al., 2014) may be expected to translate to enhanced GLS1 expression in MB 
tumours. Indeed, results obtained from the GEO repository (GEO: GSE42558) showed 
changes in GLS1 expression between MB and CB, although no significance was observed for 
GLS1 expression and patient survival in the Newcastle cohort. Despite this, using another 
online expression database (GEO: GDS4471) we show high expressing GLS1 patients have a 
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worse overall survival than low GLS1 expressing patients (Figure 3.2.2). Our proteomic data 
further reveal an importance of GLS1 expression in predicting survival (Figure 3.2.3). 
We further show no expression changes in GLS2 in MB tumours when compared to normal 
cerebellum. This aligns with several other tumour types, with studies rarely finding GLS2 
overexpression, including gliomas  (Martín-Rufián et al., 2014), liver and colon (Zhang et al., 
2013). It has been recently suggested that GLS2 has an important role in TAp73-expressing 
MB tumours. However, TAp73-overexpressing MBs only account for a fraction of these 
tumours, which may explain the differences in results between our groups. 
GLUD1, which allows the NAD(P)+ dependent release of the amine group of glutamate to 
form αKG, is an important enzyme which contributes towards TCA anaplerosis. Our results 
revealed a striking and significant alteration in GLUD1, with decreased expression found in 
the SHH, Grp3 and Grp MB subgroups, which are have a more aggressive phenotype than 
the WNT group. We also observed decreased expression in MB tumours compared to CB, 
which interestingly held up as a prognostic indicator in patients, with low expressing 
patients having a significantly poorer overall survival (OS) compared to their higher GLUD1-
expressing counterparts. The use of three independent databases helps strengthen our 
research, however, patient numbers in the GEO: GSE42558 repository are low (MB n=9 and 
CB n=4) and may therefore not be as convincing. The Newcastle cohort is much larger and 
therefore more robust, although normal cerebellar controls are lacking. Furthermore, here 
we present data as FPKM, although this may have been better presented as TMM (Trimmed 
mean of m values). We therefore suggest future experiments should use TMM as a quality 




 Overall, our findings are novel and encouraging, yet more data will be needed truly 
appreciate expression patterns and consequences in MB tumours. 
 
3.3.3 Medulloblastoma cells are dependent on glutamine for de novo glutamate synthesis. 
 
 
The importance of glutamate metabolism has previously been demonstrated in gliomas, 
where extracellular concentrations are neurocytotoxic, allowing for the increased invasion 
of glioma cells (Ye and Sontheimer, 1999; Takano et al., 2001).  Despite this, no studies have 
focused on glutamate in MB tumour biology. It has been previously reported that MB cells 
may be glutamine addicted (Niklison-Chirou et al., 2017). Our data further highlights the 
importance of this metabolite in MB, where we observed increased glutamine transporter 
expression in MB tumours and additionally demonstrated the requirement of glutamine for 
optimal cell line growth. Furthermore, we revealed the implications of glutamine catabolism 
in MB patient survival, with high glutamine turnover leading to worse clinical outcomes. The 
shift towards increased glutamine metabolism has also been implicated in ovarian tumours 
(OVCA), with glutamine dependent tumours being more invasive than their glutamine- 
independent counterparts (Yang et al., 2014). The same group also correlated heightened 
glutaminolysis with poor survival in OVCA patients, suggesting this mode of analysis may be 
useful in a number of tumours. We further investigated the relative glutamine turnover 
between our MB cells lines by incubating them with 13C-U-glutamine for 24 h and 
investigating carbon incorporation into central carbon metabolites. We found that the DAOY 
line was the most glutamine dependent cell line, with the highest 13C label incorporation 
detected in every glutamine-derived metabolite measured. Glutamine could be considered 
an ‘essential amino’ acid in cancer biology, given its central role in supporting proliferation. 
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Thus, our observations that MB cells are glutamine addicted are not surprising. We show 
here however that glutamate is unable to rescue cellular growth upon glutamine starvation, 
which aligns with our data showing low glutamate import potential in MB tumours, but 
suggests that glutamine use in these tumours may not be as simple as a requirement for 
growth. It is important to note that dimethyl glutamate - upon removal of the methyl groups 
within the cell – can result in the production of methanol, which may be toxic to cells. 
Therefore, it may be this reason why we do not observe a rescuing phenotype with this 
treatment. 
 
MB cells may also be particularly reliant on de novo glutamate biosynthesis because 
glutamate, unlike other amino acids, does not efficiently cross the BBB into the CNS (Smith, 
2000; Hawkins, 2009). Our data show that through glutaminase inhibition, due to 
specifically its effect on the GLS1 enzyme (not GLS2) significantly impacts on MB cell line 
growth. We suggest that de novo glutamate synthesis is essential in these cells. Glutamine 
acts as a “nitrogen reservoir” for cancer cells due to its role in nucleotide synthesis and it 
may be this property that makes glutamine so important in MB, although we did not explore 
this in our cell line models. Furthermore, we have not investigated the fate of ammonia in 
MB, where it is a by-product of GLS activity. Ammonia is commonly thought of as a toxic 
product of glutaminolysis, but has since been shown to be utilised in cancer cell growth (and 
therefore may have interesting implications for MB). Glutamine synthetase (GLUL) is an 
ATP-dependent enzyme which catalyses the condensation of ammonium to glutamate, 
resulting in glutamine synthesis. In many cancers, the intricate equilibrium between 
glutamine anabolism and catabolism is vital. For example, reduced GLUL activity has been 
associated with a more invasive and aggressive phenotype in some cancers. However, 
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conflicting results have been shown in glioblastoma, where GLUL expression was identified 
as a negative growth regulator (Yin et al., 2013), yet high GLUL expression has also been 
reported under reduced glutamine concentrations (Tardito et al., 2015). Our data reveal low 
GLUL expression and activity in MB, which may suggest a lower demand for glutamine-
derived nucleotide synthesis. On the other hand, this may also reflect the sustained increase 
in glutamine availability in these tumours, thus rendering GLUL obsolete. We suggest that 
although potentially important for nucleotide synthesis, glutamine is needed for 
biosynthesis of glutamate, which has several downstream fates in MB. 
3.3.4 Glutaminase 1 is the preferred isozyme under basal conditions.  
 
The relative activities of GLS isozymes have been reported in several tumours, where GLS1 
has been shown to be highly expressed in tumour cells, aiding proliferation and oncogenic 
transformation. GLS2, however, is commonly down regulated in tumours and is often 
described as tumour suppressive (Xiang et al, 2013). It is important to note that this does 
not apply to all tumour types, and therefore the role of GLS2 in tumorigenesis is unclear.  
Our results align with these common findings, where we show the expression of GLS1 is far 
higher than GLS2 in all three MB cell lines. Furthermore, when labelled with 13C-U-
glutamine, the labelled pool of glutamate was only significantly decreased after GLS1 
knockdown, while we observed no changes in labelled glutamate upon GLS2 knock-down. 
Our results suggest that under basal conditions, GLS1 activity is higher than GLS2, and was 
the main determinant of de novo glutamate synthesis. The transcription of GLS1 can result 
in two splice variant products, GAC or KGA. Despite the significant research focus on 
glutaminases, relatively few of these studies take in to account variations in GAC and KGA in 
the setting of cancer biology. Our data show clearly the relative expressions of the KGA and 
104 
 
GAC splice variants in MB cell lines, where GAC represents the major splice variant at both 
mRNA and protein expression levels. As the difference between expression is significantly 
more enhanced at the mRNA level, it suggests that there is differential regulation of mRNA 
processing between variants.  
3.3.5 Differences were observed in the localisation of GLS1 variants KGA and GAC 
 
Glutaminases are typically referred to as a mitochondrial enzymes, however, more recently 
it has been shown in breast, prostate and lung cancer cell lines that specific variants of GLS  
also exist in the cytosol (Cassago et al., 2012). The data presented here show that the GLS1 
variants demonstrate different sub-cellular localisations, with KGA predominantly localising 
in the cytosol, while GAC is typically observed in the mitochondria, with low expression also 
visualised in the cytosolic fraction of the DAOY cell line. Glutaminases are more complex 
than previously assumed, with protein structures containing additional motifs and 
functional domains independent of enzymatic abilities. Both KGA and GAC variants harbour 
transit peptides which direct them to the mitochondria, yet despite this, our results show 
cytosolic localization of the KGA variant. The differences observed between GLS variants 
may be caused by dissimilarities in their C-terminal in which they have 12% sequence 
homology. It has been predicted that KGA contains three ankyrin repeats, allowing for 
protein-protein interactions (Li, Mahajan and Tsai, 2006). Cassago and co-workers, through 
structure-based biochemical techniques, have identified five amino acids in the end 
sequence of KGA as potentially being a second NR box motif (Cassago et al., 2012), which 
may further account for differences seen between GLS variants.  
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GAC activity has been implicated more frequently than KGA in tumours, where 
overexpression of this enzyme have been detected in gliomas (Szeliga et al., 2008), breast 
cancer (Elgadi et al., 1999), adenomas and colorectal carcinomas (Turner and McGivan, 
2003). It has also been shown that GAC inhibition represses oncogenic transformation 
(Wang et al., 2010), suggesting that GAC is the main glutaminase variant in tumours. 
However, there has not been sufficient research to distinguish the key differences between 
KGA and GAC, which will be crucial in our understanding of tumours. Our data supports the 
hypothesis that GAC is key in tumourigenesis, through its direct support of cell proliferation 
in two of the MB cell lines. We further show, through the use of 13C labelled glutamine that 
siGAC reduced label incorporation into several metabolites to a greater extent than siKGA, 
indicative of increased GAC contribution to these metabolite pools. However, the 
metabolites detected by our GC-MS are predominantly TCA cycle intermediates and 
therefore are synthesised in the mitochondria, thus, making it difficult to distinguish 
between mitochondrial and cytosolic reactions. Despite this, labelling into citrate allows us 
to distinguish between reductive and oxidative metabolism, where reductively synthesised 
citrate from 13C-U-glutamate would yield m+5 labelling (directly from α-KG), while other 
labelling patterns would reflect oxidative TCA activity. Reductive carboxylation of α-KG to 
form citrate may occur both in the mitochondria and cytosol, depending on the Isocitrate 
dehydrogenase (IDH) isoform used. It is therefore interesting to see no significant changes 
when comparing siGAC and siKGA and could potentially indicate an increased use of KGA in 
the reductive production of citrate, in the cytosol. We suggest that mitochondrial located, 
GAC may be more important in TCA anaplerosis, while KGA may be responsible for (but not 
restricted to) controlling cytosolic concentrations of glutamate and its subsequent reactions. 
We were unable to comprehensively distinguish cytosolic reactions in this project, although 
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our collaboration with Dr. Jurre Kamphost will allow us to measure the effect of GLS1 
variant knockdown on cytosolic specific reactions. One such reaction of importance which 
occurs almost exclusively in the cytosol (Although the synthesis of mitochondrial GSH has 
also been shown (Lluis et al, 2005) is the synthesis of GSH. Although unproven, we 
hypothesise that KGA may be more responsible in the synthesis of GSH, and thus its activity 
may be increased under conditions of stress. We will explore this further in the following 
chapter. 
3.3.6 The importance of proline biosynthesis in MB tumours 
 
We observed increased expression of the biosynthetic genes (ALDH18A1, PYCR1 and 
PYCR2), suggestive of enhanced capacity for proline biosynthesis from glutamate. We also 
found decreased PRODH expression, which is required for the breakdown of proline, and 
thus strengthens the notion that MB tumours favour proline anabolism. Amplified proline 
biosynthesis from glutamate may offer a way in which to remove excess mitochondrial 
glutamate, and aligns with the observation of decreased GLUD1 expression in MB patient 
tumours. The synthesis of proline also offers a reducing potential from NADH or NADPH to 
P5C, therefore allowing cells to support redox homeostasis, a vital process in rapidly dividing 
cells.  
Blood to brain transport of arginine, mediated by cationic acid transporter 1 (CAT1), makes 
it the most abundant amino acid in the brain (Smith, 2000). Nitric oxide (NO) is synthesized 
from arginine by NO synthase (NOS), and the availability of arginine is one of the rate-
limiting factors in cellular NO production. The role of NO in cancers is predominantly 
unknown, although the importance of arginine itself has been extensively studied. Arginine 
can be hydrolysed by ARG1 or ARG2 to ornithine, which subsequently may be converted to 
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proline through ornithine aminotransferase (OAT) activity, which transaminates alpha-
ketoglutarate to form glutamate as a byproduct. It has previously been shown that ARG2 is 
amply expressed in MB tumours, with the downstream metabolite of arginine - polyamine, 
playing an important role in these tumours (Vardon et al., 2017). We, however, show that 
ARG1 expression is decreased in MB tumours and the low expression conveys a worse 
outcome in patients (Figure 3.2.20), suggesting arginine may not be actively used in the 
biosynthesis of proline in these tumours. This is further highlighted by the fact that our MB 
cell lines do not require arginine for growth (data not shown). Through competing 13C-tracer 
experiments, we demonstrated this in the MB cell lines by revealing how arginine is unable 
to contribute toward proline biosynthesis, despite using relatively high concentrations of 
arginine (Figure 3.2.19). When ornithine was used as a competing metabolite for 13C-U-
glutamine, however, we see a significant reduction in 13C labelled proline (glutamine-
derived), suggestive of increased ornithine-derived proline biosynthesis. We might expect 
the cells to utilise arginine, where this biosynthetic pathway is also beneficial for the 
circumvention of urea production. However, we found that the MB cell lines (and 
potentially MB tumours) have reduced ARG1 activity, which could be a way of 
circumventing ornithine-derived production of proline and preferentially use glutamate-
derived proline synthesis to circumvent increased concentrations of mitochondrial 
glutamate.  
Furthermore, we show that the addition of exogenous proline decreases growth in all three 
cell lines in a concentration dependent manner. We suggest the addition of exogenous 
proline reduces PYCR activity, reducing proline biosynthesis in our cell lines, which has been 
previously been shown to be the case in melanoma (de Ingeniis et al., 2012). As a large 
108 
 
source of proline in our cell lines, we would expect glutamate concentrations to increase as 
a result of reduced proline biosynthesis, which is what we observe when cells are fed with 
ornithine. We propose this affects the concentration of glutamate, the control of which may 
be an important mechanism to maintain tumour growth of MB.  
Interestingly, de Ingenis et al, showed that PYCR1 contributes predominantly towards 
glutamate-derived proline synthesis, but may also catalyse ornithine to proline, while PYCR2 
is used exclusively for biosynthesis of proline from glutamate (de Ingeniis et al., 2012). Our 
data suggest that PYCR2 expression – but not PYCR1 – is predictive of survival in MB 
patients, suggesting that these substrate differences in PYCR isoforms may be important in 
MB biology (i.e. MB tumours might prefer PYCR2 as it catalyses glutamate to proline). They 
further showed that PYCRL participates only in production of proline from ornithine. These 
data support our own, but also highlight gaps in our research, as we did not distinguish 
between PYCR enzymes in this study. PYCRL is a cytosolic enzyme, which converts ornithine 
but not glutamate to proline. We would therefore expect this isozyme to have little effect 
on glutamate-derived proline synthesis. 
The export of proline in tumours has also been shown to have a wider acting role, and may 
be an important and dynamic process in tumour progression (Fang et al., 2014). We 
observed labelled pools (predominantly m+5) of proline in the media of all three cell lines, 
when labelled with 13C-U-glutamine. Our results suggest that MB cell lines produce proline 
in amounts surpassing biomass requirements and excretion could be acting to remove 
excess glutamate and NADH. Collagen in the extracellular matrix (ECM) is predominantly 
comprised of proline residues, and may serve as a controlled source for proline (Phang et 
al., 2015). We have previously shown that exogenous proline may impact MB cell growth, 
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thus depositing proline into collagen could be advantageous to these tumours by reducing 
extracellular concentrations. It has been suggested that this may also be a route of survival 
in quiescent cancer cells, with many formed products being deposited as ECM collagen 
(Valcourt et al., 2012). Increased collagen deposition and remodelling produces a 
restructured microenvironment able to support tumour progression by destabilizing cell–
cell adhesion and cell polarity, and has even been shown to augment growth factor 
signalling (Paszek et al., 2005). Continued collagen remodelling may also induce changes in 
gene expression, proliferation, cell differentiation, migration (Fang et al., 2014) and has 
been linked with treatment resistance in ovarian cancer (Januchowski et al., 2016). 
Therefore, our observation of intricate collagen networks within patient tumours (Figure 
3.2.22) may have significant implications in MB. More research will be needed to explore 
this, for instance, although we show general collagen deposition, we did not classify the 
collagen type. Collagens can be divided into separate ‘types’, where type I-X are described 
as a fibrillar class. Type XII and type XXI collagens are fibril associated collagens with 
interrupted triple helices class. Type XV collagen belongs to the multiple triple helix domains 
with interruptions class, and type XVII collagen belongs to a class of membrane associated 
collagens with interrupted triple helices.  Different collagen types can have separate roles in 
cancer biology (Januchowski et al., 2016), thus their classification in MB could be important.  
3.3.7 MB cells inhibit GABA synthesis and GABAergic properties. 
 
After finding MB cells lines may synthesise proline as a way of reducing concentrations of 
potentially excitotoxic glutamate, we hypothesised that these tumours may also use GABA 
synthesis in a similar fashion. Surprisingly however, we find MB tumours significantly reduce 
the expression of the main enzyme involved in GABA biosynthesis from glutamate, GAD1. 
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These data disagree with our previous hypothesis, but present an interesting finding as 
GABA metabolism is being increasingly studied in the setting of cancers. GABA has been 
implicated in the proliferation (Takehara et al., 2007), differentiation (Liu et al., 2009), and 
migration (Shankar and Brastianos, 2014) of cancer cells. Amplified GAD activity and 
subsequent GABA concentrations have been reported in breast cancer (Shankar and 
Brastianos, 2014), colon cancer (Miao et al., 2010), gastric cancer (Matuszek, Jesipowicz and 
Kleinrok, 2001) ,prostate cancer (Christopher, 2011), and glioma (Smits et al., 2012; Pallud 
et al., 2014). Our results reveal a prominent effect of GABA in MB, with GABA biosynthesis 
being reduced in MB cell lines and GABA biosynthetic and GABAergic genes being 
downregulated in MB tumours. Separate to its role in  neurotransmission, GABA via GABA-A 
receptors can negatively regulate proliferation of pluripotent and neural stem cells in adult 
and embryonic tissue (Young and Bordey, 2009). We further show that the addition of 
exogenous GABA reduces the growth of the UW228.3 cell lines, suggesting these cells retain 
GABAergic characteristics. The ONS-76 and DAOY cell lines did not elicit the same response, 
which may be a consequence of reduced GABA receptors and transporters, reflecting the 
low mRNA expression levels observed in MB tumours. This negative effect on stem cells 
growth may reveal why MB tumours may be selected to reduce concentrations of reactivity 
to this metabolite/ligand, and we suggest that MB tumours and cell lines may reduce GABA 
concentrations to prevent negative growth/differentiation effects elicited by this 
metabolite.  
3.3.8 Glutamate exported is coupled to cystine import, via SLC7A11 anti-porter activity. 
 
The export of glutamate has been studied in the setting of cancers, where several tumours 
have been shown to release high concentrations of glutamate (Ye and Sontheimer, 1999; 
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Seidlitz et al., 2009; Fazzari et al., 2015). One of the best studied tumour for the release of 
glutamate is glioblastoma, where studies have implicated extracellular glutamate with 
increased uptake of cystine via the SLC7A11 antiporter (Huang et al., 2005), increased 
invasion through paracrine glutamate signalling (Piao, Lu and de Groot, 2009), and exported 
glutamate has more recently been shown to alter tumour associated macrophages (Choi et 
al., 2015). We found that the DAOY cell line exports glutamate at a concentration almost 4-
fold higher than the ONS-76 and UW228.3 cell lines, yet intracellular concentrations are 
relatively equal. The enzymatic properties of glutaminase may suggest one benefit to the 
heightened release of glutamate in DAOY cell line. GLS1 is potently inhibited by glutamate, 
thus, reduced intracellular glutamate as a result of glutamate export could increase GLS1 
activity, which may help achieve higher glutamine anaplerosis. We do in fact see heightened 
glutamine flux into TCA metabolites in the cell line. This fits with our previous hypothesis 
that MB cell lines utilise proline biosynthesis as a means of removing mitochondrial 
glutamate, thus multiple mechanism may be involved in maintaining an ideal intracellular 
concentration of glutamate in MB, while also being utilised in potentially vital pathways. 
Similar to research conducted in glioblastoma, we observe that glutamate export is coupled 
with cystine import, suggesting a role for the glutamate/cystine antiporter in MB. The 
inhibition of SLC7A11 with SSZ resulted in reduced MB cell line growth, suggesting an 
importance of this anti-porter in MB cell biology. However, the use of SSZ has been 
previously shown to target several other pathways and thus, the reduced cell growth 
observed may not be dictated solely by SLC7A11 inhibition. Despite this, the use of SSZ in 
the treatment of cancers have been demonstrated, where SSZ use in glioblastoma has 
potential for avoiding or greatly reducing temozolomide-associated toxicity in patients 
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(Ignarro et al., 2016), suggesting this treatment may be important in other SLC7A11 
expressing tumours. We explore the role of SSZ in MB treatment resistance in the following 
chapter.  
 
3.3.9 Potential advantages of glutamate export in MB, In addition to cystine import. 
 
Our previous data reveal low expression and activity of GLUL, where as a result, cells may be 
more susceptible to decreases in glutamine concentrations. We have indeed shown in our in 
vitro cell line models that this is the case. One way in which cancer cells have been shown to 
circumvent this is through the acquisition of glutamine from surrounding stromal cells, with 
cell of the tumour microenvironment being shown to increase their expression of GLUL 
(Castegna and Menga, 2018). The release of tumour-derived glutamate has previously been 
reported to be taken up by stromal cells and subsequently converted to glutamine via GLUL 
activity (Ye and Sontheimer, 1999). The release of glutamine can subsequently be utilised by 
tumour cells (Ko et al., 2011). This glutamate-glutamine recycling event allows tumours to 
sustain a high degree of glutamine uptake, while exporting potentially cytotoxic 
concentrations of glutamate. This is also particularly important for the heightened 
glutaminolysis and glutamate exchange for cysteine via SLC7A11.  
 
3.3.10 Summary  
 
In this chapter we highlighted how the expression of certain metabolic genes could impact 
MB biology. We further built on this information through the use of several in vitro 
techniques to pull apart to importance of glutamine and glutamate, along with other key 
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metabolites interlinked. We have shown that MB cells require glutamine to sustain optimal 
growth and the rate in which they utilise glutamine may reflect tumour aggressiveness and 
may well be prognostic in MB patients.  
MB cells have heightened glutamine uptake, of which they subsequently rely on GLS1 for 
the biosynthesis of glutamate. We have highlighted several potential roles of glutamate in 
MB, which significantly supports previous in vivo data showing glutamate as a prognostic 
marker (Wilson et al., 2014). In addition to supporting these data, we show the majority of 
glutamate detected in MB tumours is likely to be extracellular (micro environmental), which 
may have important clinical consequences. 
The tight regulation of intracellular glutamate concentrations are important due to the 
cytotoxic nature of this metabolite, especially in the brain. We have shown how proline may 
be an important metabolite in which MB cells use to divert these unwanted excess 
concentrations. Furthermore, this makes the lack of GABA synthesis interesting where we 





























Interfering with Glutamate metabolism to further 

















Whilst the molecular understanding of medulloblastoma has increased greatly in recent 
years, the translation of this into advances in the treatment of patients with  MB have been 
underwhelming, with surgery, postoperative radiation therapy (RT) and chemotherapy 
remaining the standard of care (Fossati, Ricardi and Orecchia, 2009). The lack of progress in 
the development of novel targeted treatments is in part- due to the large proportion of 
patients that are cured with such therapies, with approximately three-quarters of patients 
with standard risk disease and around 60% of those with metastatic disease achieving long-
term survival (5 or more years). Although these survival rates have increased dramatically 
over the last few decades, recent improvements have been small and long-term toxicities in 
survivors is limiting the prospect of intensifying treatment further. Extent of resection is 
significantly associated with survival in patients with glioblastoma (Lacroix et al., 2001). 
However, this does not appear to be the case in MB, where a study conducted in 787 
patients showed no such correlation of overall survival (OS) or progression-free survival 
(PFS) when comparing gross total resection with near-total resection (Thompson et al., 
2016). This places further emphasis on postoperative radiation and chemotherapy as being 
key to successful treatment. However, treatment-related toxicities are a significant problem 
with these therapies, occurring in a large proportion of long term survivors, resulting in a 
profound deterioration of quality of life (Packer and Vezina, 2008). Several forms of 
cognitive impairment have been identified in these patients, owing to the disruption of the 
normal developmental process of the growing brain (Mabbott, 2006). This has, in part, been 
circumvented by dividing patients into risk categories and reserving high dose radiation and 
chemotherapy to those patients deemed to be high-risk, while reducing such treatments in 
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low-risk patients, thereby ensuring decreased toxicities while maintaining high treatment 
efficacy. Therefore, there is need for alternative approaches to treating these tumours. 
Metabolic transformation is a hallmark of tumour biology and may offer potential targets 
for novel therapies. Since Otto Warburg’s observation of increased lactate production in 
aerobic conditions in cancer cells (Warburg, 1925), significant studies, including clinical 
trials, have examined the effectiveness of blocking this metabolic pathway to reduce 
tumour growth, or as a means to sensitising tumours to existing treatment. Such effects 
have been directed towards inhibiting metabolic phenotypes such as increased glucose 
uptake (Liu et al., 2012) and tumoural glycolysis (Pelicano et al., 2006). However, a 
significant problem with these therapies lies in the non-specific nature of targeting 
glycolysis, highlighting the need for more specific metabolic pathway targeting approaches.  
Alongside glucose, glutamine is a critically required nutrient in most if not all tumours. 
Both are crucial in order to fulfil two essential requirements in proliferating tumour cells. 
Firstly, ATP production, which is needed for cellular bioenergetics (Le et al., 2012) and 
secondly, they both provide intermediates for the synthesis of macromolecules (Stumvoll 
et al., 1999). Glutamine additionally serves as a vital source of nitrogen for amino acid 
and nucleotide synthesis, and is central to the synthesis of glutathione, a major anti-
oxidant couple, and without which cells rapidly die. Indeed, glutathione is central to 
protection of cells from cytotoxic therapy (Matés et al., 2002). The multiple critical 
metabolic pathways that glutamine feeds therefore highlights its importance in tumour 
biology, and specifically the resistance of tumours to certain therapies.  
This is underlined by the fact that glutamine use can be predictive of aggressiveness in 
several tumours, including ovarian (Yang et al., 2014), pancreatic (Son et al., 2013) and 
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colorectal cancer (Hao et al., 2016). Despite our growing understanding of the role of 
glutamine in cellular anti-oxidative protection, relatively little progress has been made 
clinically in targeting its metabolism. 
It has previously been shown that cancer cell lines are sensitised to glutamine starvation, 
including cells derived from small cell lung carcinoma, glioblastoma multiforme and acute 
myelogeneous leukemia (Wu, Arimura and Yunis, 1978).  Glutamine analogues including 6-
diazo-5-oxo-L-norleucine (L-DON), azaserine, and acivicin have also been used with varying 
degrees of success. Preclinical testing of each of these agents displayed significant 
cytotoxicity in specific tumour types, both in cell lines and in mouse xenograft models 
(Ahluwalia et al., 1990). Other efforts have been directed towards suppressing glutamine 
uptake in tumour cells (Fuchs and Bode, 2005), or blocking glutamine-dependent 
anaplerosis (Thornburg et al., 2008)  
In this chapter we explore the impact of inhibiting glutamine and glutamate metabolism in 
MB cell lines, by means of siRNA knockdowns and compound inhibition. We investigate how 
this inhibition may affect cell survival and whether or not this may increase the efficacy of 










4.2.1. Resistance to treatment varies between MB cell lines 
 
We previously observed (chapter 3) that MB cell lines have varying degrees of glutamine 
dependency. We therefore, hypothesised that these metabolic differences may lead to 
differential resistance to treatment in our cell lines. To test this, we carried out dose 
response studies on all three cell lines, using three distinct cellular stressors – gamma 
irradiation, hydrogen peroxide and cisplatin treatment. Using an SRB assay to quantify the 
change in cell viability elicited by treatments, we found that the DAOY cell line 
A B 
Figure 4.2.1 Medulloblastoma cell lines have varying degrees of treatment resistance. SRB 
viability assays of ONS-76, DAOY and UW228.3 cell lines when irradiated (0-20Gy), treated 
with hydrogen peroxide (0-500µM) and Cisplatin (0-100 µM). Cells were then fixed after 24h 
and assessed for viability. Data presented as mean ±SEM representative of three separate 
experiments. Significance was determined by performing a one-way ANOVA with Tukey 





demonstrated the highest resistance to irradiation and H2O2, with IC50s of; undetermined 
Gy and 375µM, respectively (figure 4.2.1). ONS-76 cells showed intermediate treatment 
resistance, while, the UW228.3 cell line was the most sensitive. Interestingly, there was no 
differential sensitivity observed between cell lines and treatments suggesting that relatively 
few; perhaps even a single mechanism of resistance was being used by the MB cells. 
4.2.2 Starving MB cell lines of glutamine sensitises them to treatment 
 
Our previous findings that MB cell lines require glutamine to sustain competent growth led 
us to hypothesise that glutamine may also be required for cellular survival. To better 
understand glutamine dependence in this setting, we investigated MB cell line sensitivity to 
cisplatin and hydrogen peroxide treatment, under glutamine sufficient and glutamine-
deprived conditions. We found that after 12 hours of glutamine starvation, all three MB cell 
lines became increasingly sensitised to both cisplatin and hydrogen peroxide treatment, 
with the DAOY cell line showing the largest dependency on glutamine for treatment 
resistance. This significance was confirmed by two separate assays, an SRB cell viability 
assay (Figure 4.2.2.A) and with an AnnexinV/PI flow cytometry apoptosis assay (Figure 
4.2.2.B). We therefore demonstrated that glutamine is essential for a successful response to 







4.2.3 De novo glutamate synthesis drives treatment resistance 
 
After our finding that glutamine is important in the protection against cytotoxic agents, we 
investigated whether this was driven through the de novo production of glutamate. To 
achieve this, we knocked down the major glutaminase isozyme - GLS1 – and treated with 
cisplatin or gamma irradiation. These two agents were chosen as they are both very relevant 
treatments for MB patients. Using an SRB assay, knockdown of GLS1 revealed an increased 




































































































































































































































Figure 4.2.2. Glutamine starvations sensitises MB cell lines to treatment. A) An SRB viability 
assay was carried out to determine the effectiveness of glutamine deprivation on ONS-76, DAOY 
and UW228.3 cell lines. Cells were cultured in 0mM glutamine for 12h prior to being treated with 
DMSO, hydrogen peroxide and cisplatin. B) Cell death was further examined using a flow 
cytometry AnnexinV/PI assay. Cells were cultured in 0mM glutamine for 12h prior to being 
treated with DMSO, hydrogen peroxide and cisplatin. Data presented as mean ±SEM 
representative of three separate experiments. Significance was determined by performing a one-








that seen under glutamine starvation. However, in the ONS-76 cell line, siGLS1 did not 
sensitise to treatment when assessed by an SRB assay. Knockdown of GLS1 only revealed an 
increased sensitisation to and irradiation in the UW228.3 line (Figure 4.2.4 A). Furthermore, 
in contrast to the glutamine depletion experiment, the UW228.3 cell line showed the largest 















Figure 4.2.3. Knockdown of GLS1 leads to increased cytotoxicity of cisplatin in MB cell lines. 
A) An SRB viability assay was carried out to determine the effectiveness of GLS knockdown on 
ONS-76, DAOY and UW228.3 cell lines. Cells were treated with siNT, siNT+cisplatin, siGLS1 
and siGLS1+cisplatin. Knockdown of GLS1 decreased the cell viability of all three cell lines to 
cisplatin treatment. B) Cell death was further examined using a flow cytometry AnnexinV/PI 
assay. Data presented as mean ±SEM representative of three separate experiments. 
Significance was determined by performing a one-way ANOVA with Tukey post-hoc test in 
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The magnitude of the cell death response measured using the SRB assay was examined 
using an alternative, direct measure of loss of cell viability – annexin V/PI staining of cell and 
analysis through flow cytometry. A significant reduction of cell viability (in all three lines) 
was observed using this assay, after either cisplatin or irradiation treatment (Figure 4.2.3B 






















Figure 4.2.4 Knockdown of GLS1 leads to increased cytotoxicity of irradiation treatment in 
MB cell lines. A) An SRB viability assay was carried out to determine the effectiveness of GLS 
knockdown on ONS-76, DAOY and UW228.3 cell lines. Cells were treated with siNT, siNT+10Gy 
Irradiation, siGLS1 and siGLS1+10Gy Irradiation. Knockdown of GLS1 decreased the cell viability 
of all three cell lines to irradiation treatment. B) Cell death was further examined using a flow 
cytometry AnnexinV/PI assay. Data presented as mean ±SEM representative of three separate 
experiments. Significance was determined by performing a one-way ANOVA with Tukey post-
























































































































































































































4.2.4 GLS1 maintains redox balance through synthesis and maintenance of glutathione 
 
Glutamate is the major precursor of glutathione synthesis, being both a substrate of the 
tripeptide, and a necessary component for the synthesis or import of the other two amino 
acids required – cysteine and glycine. Therefore, we measured isotopic label incorporation 
from 13C-U-glutamine into both reduced glutathione (GSH) and oxidised glutathione 
(glutathione disulphide; GSSG) using liquid chromatography- mass spectrometry (LC-MS) in 
the ONS-76 cell line, in collaboration with Dr. Jurre Kamphorst (University of Glasgow, UK). 
The mass isotopomer distribution (MID) of GSH using labelled glutamine revealed a 
significant reduction of labelled GSH when GLS was knocked down, with a reduction of over 
50% seen for the m+5 isotopomer (representative of the incorporation of a single glutamate 
molecule into GSH; Figure 4.2.5.A) and a smaller, yet significant reduction seen for the m+5 
& m+10 isotopomer for GSSG (the incorporation of one [m+5] or two [m+10] glutamate 
molecules into GSSG). We also investigated the redox status of the ONS-76, DAOY and 
UW228.3 cell lines upon siNT or siGLS1, a marker of which is the GSH/GSSG ratio (Figure 
4.2.5.C). A decreased ratio of reduced GSH to GSSG was observed siGLS1, confirming that 
GLS1 is important for maintaining the cellular protection against oxidative stress in MB cell 















































































Figure 4.2.5. Knockdown of GLS1 leads to decreased glutathione synthesis and reduces the 
GSH/GSSG ratio in MB cell lines. A) Analysis of the mass isotopologue distribution (MID) of 
reduced glutathione after treatment with H2O2 treatment in the ONS-76 cell line only. Mass 
isotopomers (m+0, m+1, m+2, m+3, m+4 and m+5) correspond to ion fragments containing 
different 13C atoms. Alterations in reduced glutathione labelling after H2O2 treatment are 
present in the DAOY and UW228.3 cell lines. B) MID analysis of oxidised glutathione shows 
decreased labelling with siGLS1. Diagram (C) describes the maintenance of reduced (GSH) 
and oxidisied (GSSG) glutathione. D) GSH:GSSG is decreased with siGLS1, as measured with a 
GSH/GSSG ratio detection assay kit. Data is performed in technical triplicate, mean +/- S.D. 
Statistical significance determined using two-tailed unpaired Student’s t-test; *p<0.05, 


















































































































































































































































































































Figure 4.2.6. Pre-treatment with BPTES leads to increased cytotoxicity of Cisplatin treatment in MB cell 
lines. A) Cell death was examined using a flow cytometry AnnexinV/PI assay to determine the effectiveness 
of BPTES on ONS-76, DAOY and UW228.3 cell lines. Cells treated with DMSO, BPTES, Cisplatin or a 
combination of BPTES and cisplatin. BPTES pre-treatment 24 hours prior to cisplatin treatment decreased 
the cell viability of all three cell lines. Data presented as mean ±SEM representative of three separate 
experiments. Significance was determined by performing a one-way ANOVA with Tukey post-hoc test in 
Graphpad; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. B) MID analysis of glutamate, comparing siGLS1 
and BPTES. No differences between GLS KD and GLS inhibition was seen. C) Steady state concentrations of 
glutathione are decreased with BPTES treatment, as quantified by 1D 1 H-NMR spectroscopy. Data is mean 
+/- S.E.M and representative of at least three biological replicates. Significance determined using two-tailed 





4.2.5. Pre-treatment with BPTES leads to a potentiation of treatment. 
 
High doses of chemotherapy given to children with MB often result in adverse side effects, 
leading to decreased quality of life. We therefore, decided to use cisplatin in co-treatment 
with BPTES to see whether the GLS1 inhibitor could potentiate the effects of these cytotoxic 
agents, thereby providing a means of reducing cytotoxic agent dose that would be needed 
to treat MB. As before, an annexin/PI cell death assay  was performed to determine changes 
in cell viability. When pre-treated for 8hr with BPTES, the DAOY and UW228.3 cell lines 
showed decreased viability after cisplatin treatment when compared to BPTES and cisplatin 
treatment alone (figure 4.2.6).  However, no significant difference was observed in the ONS-
76 cell line, consistent with previous data showing that siGLS1 is least effective on the cell 
line. 
4.2.6 GLS2 protects MB cell lines against cytotoxic agents 
 
Several studies have identified GLS2 as being important in the protection against oxidative 
stresses (Martín-Rufián et al., 2014 and Suzuki et al., 2010). Despite GLS2 not being highly 
expressed under basal conditions in our MB cell lines, we observed increased GLS2 
expression after treatment with H2O2 (Figure 4.2.7). We sought to investigate whether this 
increase in GLS2 expression played a role in the defence against cytotoxic agents. To 
investigate this, we tested the effect of siGLS1, siGLS2 and siGLS1 and siGLS2 combined. 
Similarly to our previous experiments, we observed that GLS1 KD increased sensitivity to 
treatment in all three cell lines (Figure 4.2.4). Our results also show increased cell death in 
all three cell lines upon GLS2 KD, suggesting a role for this enzyme in the protection against 
treatment. A combination of siGLS1 and siGLS2 further potentiated H2O2 treatment in the 
















4.2.7. SLC7A11 inhibition can increase hydrogen peroxide cytotoxicity in MB cell lines.  
 
The synthesis of glutathione from cytosolic glutamate requires two further amino acids; 
cysteine and glycine.  A major route for the import of cysteine from the extracellular space is 
through its dipeptide (cystine), which is anti-ported against glutamate by the xCT (SLC7A11) 
transporter. Our previous data suggested that a major fate of glutamine-derived glutamate 
in MB cells was its excretion into the medium (Chapter 3). We investigated whether 




















Figure 4.2.7. GLS2 expression increases with H2O2 treatment, leading to treatment resistance. 
Immunoblot analysis showing increased expression In GLS2, but not GLS1 after treatment with H2O2. 
Actin was probed as a loading control. B) Cell death was examined using a flow cytometry AnnexinV/PI 
assay to determine the effectiveness of siGLS1, siGLS2 or both on ONS-76, DAOY and UW228.3 cell lines. 
siGLS1, siGLS2 and both decreased the cell viability of all three cell lines. Data presented as mean ±SEM 
representative of three separate experiments. Significance was determined by performing a one-way 





treated cells with sulfasalazine, an inhibitor of the cystine/glutamate antiporter known as 
the xCT transporter (SLC7A11), and observed a decrease in intracellular cysteine 
concentrations (Figure 4.2.8A). This treatment also sensitised cells to hydrogen peroxide 
treatment (Figure 4.2.8C), which we show is likely due to decreased intracellular GSH:GSSG 
ratios (Figure 4.2.8B) caused by SZZ treatment. Importantly, this effect could be abolished 
















































































Figure 4.2.8. SLC7A11 is required for cystine uptake, and resulting maintenance of 
glutathione in MB. A) An SRB viability assay was carried out to determine the importance 
of SLC7A11 in ONS-76, DAOY and UW228.3 cell lines. Cells were treated with DMSO, SSZ, 
H2O2, SSZ and H2O2, or SSZ, H2O2 and 2-ME. A)  GC-MS analysis showed a reduction of 
intracellular cystine upon treatment with SZZ. B) Sulfasalazine (SSZ) treatment led to a 
sensitisation towards hydrogen peroxide treatment, which importantly could be abolished 
by the addition of 2-mercaptoethanol (2-ME).  C) SSZ treatment decreased the GSH:GSSG. 




the uptake of cystine independently of the xCT transporter by reducing cystine to cysteine, 
allowing its uptake through an alternate transporter (Figure 4.2.8D) 
 
4.2.8 Genes involved in GSH synthesis predict outcome in MB patients 
 
We have highlighted the importance of GSH in the resistance to a wider range of treatments 
in our MB cell lines. We further assessed the importance of genes that control and modulate 
GSH in MB tumours, through two separate mRNA databases. We observed increased 
expression of GCLC-which encodes the rate limiting enzyme in the synthesis of GSH- in MB 
tumours compared to normal cerebellum. We further show GCLC expression is higher in 
SHH, Grp3 and Grp4 MB compared to WNT tumours, suggesting expression is coupled with 
a more aggressive phenotype, although, this is not quite reflected in our Newcastle survival 
cohort despite a strong trend. Furthermore, we detected clinical significance in GSR 
















































































4.2.9 Hydrogen peroxide treatment alters glutamine metabolism. 
 
The investigations to this point have examined the sensitivity of MB cell lines to treatment 
after glutamine pathway manipulations, however, they have not provided any information 
as to the response of MB cell line metabolism to treatment. To better understand this, we 
measured isotopic label incorporation from 13C-U-Glutamine during treatment with the 
oxidant, hydrogen peroxide. We found that the most sensitive cell line, UW228.3, 
demonstrated an increased flux of glutamine into glutamate, while a smaller increase was 
observed in the DAOY cell line. No significant changes were noted in the ONS-76 cell line 
(Figure 4.2.8).  
Figure 4.2.9. Expression of glutathione-related genes was associated with survival in MB 
tumours.  A) RNA expression data compared across subgroups of MB and representative 
Kaplan-Meier survival curves of the MB Newcastle cohort. n=240 (WNT n=28, SHH n=58, G3 
n=59 and G4 n =95). High and low expression was determined by the median expression 
value for each gene. Log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon statistical tests 


























































































































































) C o n tro l H 2 O 2
Figure 4.2.10. Hydrogen peroxide treatment alters glutamine-derived glutamate metabolism 
between MB cell lines. Analysis of the mass isotopologue distribution (MID) of glutamate after 
treatment with H2O2 treatment. Mass isotopologues (m+0, m+1, m+2, m+3, m+4 and m+5) 
correspond to ion fragments containing different 13C atoms. Alterations in glutamate labelling 
after H2O2 treatment are present in the DAOY and UW228.3 cell lines. Data is performed in 
technical triplicate; mean +/- S.D. Statistical significance determined using two-tailed unpaired 
Student’s t-test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 




To further understand the alterations on metabolism upon hydrogen peroxide treatment, 
we investigated the changes in glutamine contribution towards several TCA cycle 
metabolites. Increased m+5 αKG was observed in the DAOY and UW228.3 lines after 
treatment, while no changes were seen in the ONS-76 cells. Hydrogen peroxide increased 
m+5 succinate and m+5 malate in the DAOY cell line only. Small increases in m+5 fumarate 
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5.2.10 Hypoxia increases MB treatment resistance  
 
Hypoxia is a regular feature of solid tumours and is frequently associated with increased 
treatment resistance. We performed immunohistochemical analyses of SHH-derived MB 
tumour tissues to determine the extent of CAIX staining (Figure 4.2.12), a commonly used 
marker of hypoxia. Our results highlight levels of CAIX staining within regions of the tumour 
tissue (Figure 4.2.12) and (Supplementary figure 4), suggesting MB tumours may harbour 













Figure 4.2.11. Hydrogen peroxide treatment elicits distinct and separate glutamine 
metabolism between MB cell lines. Analysis of the mass isotopologue distribution (MID) of α-
ketoglutarate, succinate, fumarate and malate after treatment with H2O2 treatment. Mass 
isotopomers (m+0, m+1, m+2, m+3, m+4 and m+5) correspond to ion fragments containing 
different 13C atoms. Alterations in glutamate labelling after H2O2 treatment are present in the 
DAOY and UW228.3 cell lines. Data is performed in technical triplicate, mean +/- S.D. Statistical 

























Figure 4.2.12. CAIX staining reveals hypoxic regions in MB tumours. CAIX 
protein expression is increased in MB tumours compared to controls. 
Scale bar, 50 μm.  
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5.2.11 MB cell lines switch to reductive metabolism in response to hypoxia 
 
Cells typically remodel their metabolism in response to hypoxia, a major goal of which is 
likely to support oxygen-independent ATP production. To investigate the metabolism of 
glutamine in MB cell lines in hypoxia, cells were incubated for 24 hours with [U-13C5]-
glutamine in either 21% O2 (normoxia) or 1% O2 (hypoxia). The incorporation of 
13C into 
citrate can be used to evaluate the relative extent of oxidative and reductive glutamine 
metabolism (Figure 4.2.13). The ONS-76, DAOY and UW228.3 cells displayed increased m+5 


















Figure 4.2.13. Hypoxia induces reductive glutamine metabolism. Comparison of the MID 
in citrate employing a [U-13C5]-glutamine tracer to assess the relative contributions of 
oxidative and reductive TCA activity. In normoxia, glutamine-derived αKG undergoes 
oxidative TCA metabolism producing M+4 citrate from M+4 TCA cycle intermediates. In 
hypoxia, ONS-76, DAOY and UW228.3 cells increase their reliance on reductive 
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5.2.12 Hypoxia increase treatment resistance in MB cell lines 
 
To investigate the role of hypoxia in treatment resistance, we incubated our cell lines in 
either 21% or 1% O2 for 24h prior to H2O2 treatment, which is long enough to induce HIF1α 
expression (Figure 4.2.13 D). We observed that hypoxia has a significant protective effect in 
the ONS-76 and UW228.3 cell lines (Figure 4.2.13 A-B); suggesting hypoxia may play a role in 
treatment resistance in a subset of MB tumours. We hypothesised that as a reducing 
environment, hypoxia could potentially act in a similar fashion to 2-ME, therefore rendering 
the SLC7A11 anti-porter obsolete. To test this theory we incubated our MB cell lines in 21% 
O2 and 1% O2 and subsequently treated them with the SLC7A11 inhibitor, SSZ. Our results 
demonstrate that SSZ has no additional effect on treatment resistance, confirming our 
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Figure 4.2.13. Hypoxia alters treatment resistance. SRB viability assays of ONS-76, DAOY and 
UW228.3 cells treated with H2O2 at 21% or 1% O2. A) Qualitative microscopic evaluation of SRB 
stained cells shows increased cell viability of ONS-76 and UW228.3 cells at 0.3% O2 when 
compared to 21% O2 B) Absorbance values of SRB stain confirm increased cell viability in the 
ONS-76 and UW228.3 lines at 0.3% O2 when compared to 21% O2. n=3. Data was analysed using a 
one way ANOVA with a Tukey post-hoc test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
ONS-76      DAOY     UW228.3 




4.3.1. Introduction  
 
The important role that glutamine plays in cancer development has long been appreciated. 
However, approaches that interfere with glutamine metabolism to improve therapeutic 
outcomes have been less than ideal. Glutamine is likely to elicit a resistance phenotype 
through the synthesis of glutamate, where this metabolite is utilised both directly and 
indirectly in the synthesis of glutathione (Shelly C. Lu, 2014). More recent studies have 
focused on this outcome of glutamine catabolism, with particular focus on GLS. Elegant 
work regarding glutamine metabolism has previously been carried out in lung squamous cell 
carcinoma (SCC), where it was shown  that the inhibition of GLS with CB-839 can effectively 
overcome therapeutic resistance (Momcilovic et al., 2018).  
Many tumour types have been dubbed ‘glutamine addicted’ and show sensitivity when 
subjected to a glutamine-starved diet (Chakrabarti et al., 2015). However, the importance of 
glutamine in MB tumours is only just becoming established. Wilson et al retrospectively 
analysed patients with MB using 1H magnetic resonance spectroscopy (MRS) and identified 
that glutamate was a robust marker of survival (Wilson et al., 2014). The identification of 
glutamate as a prognostic biomarker in this setting highlighted the importance of further 
studies into MB tumour metabolism, and in particular the relationship between glutamine 
and glutamate. Furthermore, it was recently shown that p73 status was linked to glutamine 
dependency in MB, where it was demonstrated that p73 expression regulated glutamine 
metabolism, in order to preserve cell growth and proliferation (Niklison-Chirou et al., 2017). 
This same group were also the first to disrupt glutamine metabolism in the context of MB, 
strengthening our notion that glutamate is important in the context of this tumour type. 
However, they direct their attention towards the inhibition of p73 and GLS2, while we 
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establish the importance of both glutaminase isozymes, GLS1 and GLS2, and consider wider 
implications of glutamate metabolism.   
4.3.2 Glutamine starvation sensitises MB cells to treatment. 
 
The combination of glutamine starvation with cisplatin causes a significant cell death 
response in our MB cell lines (Figure 4.2.2). This response to cisplatin, in part, could be due 
to a mitochondria ROS response known to be prompted by cisplatin treatment (Marrache, 
Pathak and Dhar, 2014), where reduced glutamine and resulting glutamate may lead to a 
reduced mitochondrial potential and thus, potentiating the effect of cisplatin. Our results 
are consistent with previously published data (Niklison-Chirou et al., 2017), who show a 
similar effect in MB cell lines. This same group also validated their results in an in vivo 
mouse model of MB, where a diet of reduced glutamine induced a substantial increase in 
the overall survival of these mice. However, it is important to note that these results were 
only observed in p73-expressing MB mice, which only represent a small subset of MB cases. 
Despite this, our combined work highlights the importance of glutamine in the resistance of 
MB tumours to treatment, and reveals a potential therapeutic option in these patients.  
Starving tumours of metabolites they are ‘addicted’ to, or in some case dependent on is an 
exciting therapeutic prospect. One example of this comes from acute lymphoblastic 
leukaemia (ALL), which are reliant on asparagine uptake for survival. Asparaginase therapy is 
now a cornerstone for ALL treatment where they are consistently  improving clinical 
outcomes in children (Pieters et al., 2011). The administration of asparaginase results in 
rapid and complete deamination of the amino acid asparagine but also, although to a lesser 
extent, glutamine (Avramis, 2012). This off targeting effect on glutamine may therefore 
prove useful in glutamine-addicted tumours. Although, thus far its use in solid tumours has 
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been ineffective, as in the case of ovarian cancer (HAYS et al., 2013), where serious side 
effects are commonly observed. However, it has recently been suggested that L-
Asparaginase delivered to the tumour directly by engineered Salmonella typhimurium could 
bypass these toxicities. Kim et al, demonstrated that these ‘mutant’ L-Asparaginases could 
effectively target MC38 (colon carcinoma) tumours which had been ectopically grafted into 
mice, with few side effects observed (Kim et al., 2015). It is important to note that these 
treatments will be most effective in cells reliant on asparagine, which our cell lines are not 
(data not shown), although the extent of glutamine clearance through asparaginase 
treatment may be enough to elicit responses, yet low enough prevent the significant 
toxicities, associated with glutamine analogue usage. Interestingly, there has been emerging 
research exploring the role of glutamine in the protection of normal tissue to cytotoxic 
treatments. Savarese et al, suggest that reduced glutamine concentration could have a 
bearing on the tolerance of normal tissue to antitumor treatments. They further propose 
that supplementing patients with glutamine during cancer treatment has the potential to 
nullify treatment-related toxicity (Savarese et al., 2003).  
These data reveal the complicated nature associated with clearing glutamine in the tumour 
microenvironment. The need for more targeted therapies may therefore prove more 
beneficial. 
4.3.3 The impact of interrupting de novo glutamate synthesis on the cytotoxic response to 
treatment, by inhibiting GLS1. 
 
GLS1 knockdown was utilised to study the effect of glutamate on therapy resistance, as this 
resulted in a drastic decline in glutamate synthesis in our previous studies. We then 
followed up these results with compound inhibition with BPTES, which although it 
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introduces potential complications through off target effects, provides an opportunity for 
translation to the clinic.  
Knockdown of GLS1 potentiated the cytotoxicity of cisplatin in our MB cell lines (Figure 4.2.3 
& 4.2.4), suggesting that blocking the conversion of glutamine to glutamate may increase 
the efficacy of chemotherapy in MB tumours. Interestingly, the effect of GLS knockdown 
was more profound in the UW228.3 cell line, despite these cells being less reliant on 
glutamine when compared to the DAOY cells. This suggests the effect may be less 
dependent on cell line reliance on glutamine, but instead may be reliant on glutaminase 
expression - UW228.3 cells have a relatively low expression of GLS1 in comparison to the 
other two lines. Gaining understanding of different responses through the use of multiple 
cell lines is likely to lead to more successful therapies, given the heterogeneous nature of 
MB tumours. However, we found our results were altered between cell death assays, where 
killing potentiation became significant across all cell lines with the AnnexinV/PI assay, 
compared to variations with the SRB assay. The differences between the two techniques 
proved to be an issue throughout our experiments, but may be reflective of the sensitivity 
differences between the two assays, or what they actually measured. The AnnexinV/PI assay 
utilises the binding of externalised phosphatidylserine (PS) in cells undergoing apoptosis by 
annexin V, and  cells with non-coherent plasma membranes (i.e. dead) using propidium 
iodide (Peixoto, de Oliveira Galvão and Batistuzzo de Medeiros, 2017). Therefore, this assay 
is able to identify those cells undergoing apoptosis earlier than the SRB assay and provides a 
more valuable tool when assessing cellular death responses. Following our results with 
regards to the impact of GLS1 knockdown on cisplatin cytotoxicity, we investigated whether 
this effect would be reproduced with gamma irradiation. We observed similar results (Figure 
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4.2.4), which highlighted GLS1 as a possible target with the potential to improve the efficacy 
of radiotherapy in MB tumours. 
These are important proof of concept studies, which help identify potential therapeutic 
targets. However, as GLS1 inhibitors have been trialled in the clinic, we believe that it was 
important to test this in the MB cell line models. BPTES is an allosteric inhibitor of the 
dimer-to-tetramer transition of KGA GLS, which is required for its activation. BPTES pre-
treatment was found to increase the effectiveness of cisplatin treatment in MB cell lines 
(Figure 4.2.6), strengthening the notion that GLS inhibition could be used to improve the 
efficacy of chemotherapeutic agents in MB tumours. 
Another GLS1 inhibitor becoming more commonly used is Compound 968. However, we did 
not observe any additive effect on killing with pre-treatment of this agent (Supplementary 
figure 4). The mode of action of compound 968 is different to that of BPTES, where this 
inhibitor preferentially binds to the monomeric (inactive) form of GLS, and as a result 
prevents the dimerization required for GLS activation (Stalnecker et al., 2015). Therefore, 
compound 968 is unable to inhibit GLS when the enzyme is already in an active 
conformation. We believe our cell lines are utilising GLS1 to such a degree that the majority 
of the enzyme is already in its active, dimeric form, and may explain why we do not see an 
effect in our cell lines upon treatment.  
4.3.4 GLS maintains glutathione homeostasis in order to resist cytotoxic treatments. 
 
The effectiveness of GLS1 inhibition on treatment potentiation appears to be linked to 
glutathione homeostasis. We revealed a synergistic effect of reduced glutathione and 
improved treatment efficacy – our results showed a decrease in glutathione flux when GLS1 
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was knocked down in the ONS-76 cell line (Figure 4.2.5). To confirm, we then showed that 
knockdown of GLS decreased the GSH:GSSG in all three cell lines,  suggesting the increased 
sensitisation of GLS1 KD cells to treatment is likely to be due to a defective GSH response.  
4.3.5 The impact of interrupting de novo glutamate synthesis on the cytotoxic response to 
treatment, by inhibiting GLS2. 
 
GLS2 has recently been characterised as a p53 target gene, able to protect against oxidative 
stress (Suzuki et al., 2010). Since this observation, several lines of research have highlighted 
the importance of GLS2 in the protection against ROS (Hu et al., 2010). Xiang et al, Knocked 
down GLS2 and showed a decrease in glutathione and NADH, which was able to sensitize 
cervical cancer to ionizing radiation (Xiang et al., 2013). Furthermore, the importance of 
GLS2 in MB tumours was investigated by Niklison-Chirou et al, where they concluded that 
p73 regulates GLS2 to maintain glutathione levels. They show pre-treatment with 
compound 968 increases cell line sensitivty to cisplatin, although they claim that compound 
968 acheives this by inhibiting GLS2  (Niklison-Chirou et al., 2017). However, this drug has 
only been shown to inhibit the GLS1 splice variant, GAC (Wang et al., 2010). Furthermore, 
our data represented here (Figure 4.2.7) only showed very low expression of GLS2 in all MB 
cell lines tested in basal conditions. We also demonstrated that GLS1 was the preferred 
isozyme under basal conditions. 
We also extended the investigations to the role of GLS2 in the protection against treatment 
and showed, surprisingly, that GLS2 knockdown could increase the cytotoxicity of hydrogen 
peroxide (Figure 4.2.8), despite low basal expression in our MB cell lines. Furthermore, 
despite GLS2 having little role under basal conditions, our data suggested that GLS2 
becomes ‘more active’ under conditions of stress, where we showed that GLS2 expression is 
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increased after treatment with H2O2. A potential explanation for siGLS2 increased 
sensitisation therefore, may be that knocking down GLS2 prior to treatment prevents the 
increase in its expression. We therefore show here the importance of GLS2 expression in MB 
treatment resistance, justifying further research with an aim to progress into the clinic. 
However, there are currently no compound inhibitors of GLS2 in clinical trials and only 
recently has there been the identification of a group of compounds able to inhibit GLS2 in 
vitro (Lee et al., 2014). Lee and colleagues, have identified a group of Alkyl benzoquinones 
as novel inhibitors of GLS2, the use of which leads to mTORC1 inhibition and results in 
reduced tumorigenesis (Lee et al., 2014). It will be interesting to see the use of these 
inhibitors in future studies. 
4.3.6 The impact of interrupting glutamate metabolism on the cytotoxic response to 
treatment, inhibiting SLC7A11. 
 
The glutamate/cystine antiporter (SLC7A11) has been associated with treatment resistance 
in several tumours, as it facilitates cellular uptake of cystine for the synthesis of intracellular 
GSH (Huang et al., 2005). Polewski et al, Inhibited SLC7A11 with sulfasalazine (SSZ) and 
showed a decrease in glioma cell growth and survival. This group also co-treated with SSZ 
and the chemotherapeutic agent temozolomide and revealed a synergistic killing effect 
(Polewski et al., 2016). SLC7A11 has also been highlighted as a target in triple-negative 
breast cancer (Timmerman et al., 2013). Our data suggested that MB tumours express 
SLC7A11, and blocking of this anti-porter with SSZ reduced the growth of our MB cell lines. 
Furthermore, we found that inhibiting SLC7A11 with SSZ renders MB cell lines sensitive to 
hydrogen peroxide treatment. The MB cell lines used demonstrated a degree of 
heterogeneity with respect to glutaminase expression and inhibition sensitivity, but with 
respect to SCL7A11 inhibition, all three cell lines responded similarly. Unsurprisingly, we 
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confirmed the importance of GSH in the resistance against treatment, where SSZ 
significantly reduced intracellular concentrations of cystine which subsequently decreased 
the GSH:GSSG  ratio in the MB cell lines.  We demonstrated the specificity of SSZ treatment 
by displaying how this effect could be abolished by the addition of the reducing agent, 2-
mercaptoethanol (2-ME), which facilitates the uptake of cystine independently of the xCT 
transporter by reducing cystine to cysteine, allowing its uptake through an alternative 
transporter. Our findings align strongly with studies carried out in colorectal cancer, where 
Ma et al showed SSZ was able to sensitise colorectal cancer cell lines to cisplatin through a 
GSH-depleting mechanism (Ma et al., 2015). Our results reveal an alternate target of 
glutamate metabolism for MB tumours, independent of glutaminase, which could 
potentially be used clinically. 
SSZ is an FDA approved, anti-inflammatory drug used clinically in the treatment of 
rheumatoid arthritis and inflammatory bowel disease, with few side-effects observed 
(Combe et al., 2009). The use of SSZ both in vitro and in animal studies for the treatment of 
cancers is becoming more popular in recent years. However, progress into clinical trials has 
been limited and the two trials conducted in gliomas have produced unfavourable results. 
The first of these was a phase 1/2 prospective, randomised trial in 10 patients (2 anaplastic 
astrocytoma and 8 glioblastoma), where SSZ was unable to induce clinical responses and 
was subsequently discontinued due to unacceptable toxicities (Robe et al., 2009). The 
second trial also observed no clinical benefit when SSZ was used together with 
temozolomide and radiation therapy (Takeuchi et al., 2014). These trials suggest the use of 
SSZ does not represent a potential novel means of treating glioblastoma. However, its use in 
the prevention of colorectal cancer in patients with heightened risk has been demonstrated. 
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A retrospective study of ulcerative colitis patients revealed that individuals receiving long-
term SSZ were at a significantly reduced risk of developing colorectal cancer  (Moody et al., 
1996). It has been recently observed that treatment failures using SSZ may be a direct 
consequence of activated resistance pathway in cancer. Kim et al, identified Nutrient-
deprivation autophagy factor-1 (NAF-1) as being associated with resistance to SSZ-induced 
ferroptosis. These findings highlight the need of further research investigating the 
mechanisms governing treatment failures. This also reveals a gap in our own research as we 
did not explore the mechanism of cell death in our MB cell lines to SSZ treatment, despite 
several studies showing a significant role for ferroptosis.  
Interestingly, SLC7A11 activity has been shown to amplify glutamine anaplerosis in A549 
cells, thus increasing the need for glutamine. The triggering of SLC7A11 expression, through 
the use of NNRF2-activating agents, sensitised tumours to GLS inhibitors (Koppula et al, 
2017). Thus, there may be a potential for this treatment to be used in conjunction with GLS 
inhibitors.   
4.3.7 Glutathione related genes can predict survival in MB patients 
 
Increased GSH concentrations are often observed in several tumours, correlating with 
increased resistance to therapy. Expression of specific genes encoding GSH biosynthetic 
enzymes may therefore provide information as to whether a tumour may be chemo-
resistant. GSH has previously been implicated in the chemoresistance of MB, where GSH 
supplementation protected MB cells to campthothecin related apoptosis (Li et al., 2009). 
Furthermore, Friedman et al. showed elevation in GSH and γ-glutamyl transpeptidase 
(which catalyses the transfer of gamma-glutamyl l groups from GSH, a key process in the 
gamma-glutamyl cycle) in a Cyclophosphamide (4-HC) resistant DAOY line. They confirmed 
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the role of increased GSH with 4-HC resistance by depleting GSH with L-buthionine-
sulfoximine and showing a sensitisation to this agent (Friedman, Kaufmann and Ludeman, 
1992). Through our in vitro cell line experiments, we have further highlighted the 
importance of GSH in the resistance to a wider range of treatments in MB. We also assessed 
whether genes involved in GSH metabolism held clinical relevance and observed increased 
expression of GCLC, the rate limiting enzyme in the synthesis of GSH, in MB tumours 
compared to normal cerebellum. We further show GCLC expression is higher in SHH, Grp3 
and Grp4 MB compared to WNT tumours, suggesting expression is coupled with a more 
aggressive phenotype, although, this is not quite reflected in our Newcastle survival cohort 
despite a strong trend. Furthermore, we detected clinical significance in GSR expression, 
with highly expressing patients having a poorer overall survival. GRS is vital in the salvaging 
of GSH from GSSG but becomes less efficient during periods of oxidative stress. It is 
therefore not surprising that the expression of GSR is typically increased in a number of 
tumours and has previously been used to predict responses to cisplatin in patients with lung 
cancer (Ogawa et al., 1993). Our data therefore suggests GSH plays an important role in MB 
resistance towards treatment. Furthermore, the expression of glutathione peroxidases 
(GPx1 and GPx4) – enzymes responsible for reducing lipid hydroperoxides – can be used to 
predict survival in MB patients (Supplementary figure 5). 
It has also been proposed that GSH may act as a glutamate store, preventing glutamate-
dependant neuronal excitotoxicity (Chen and Swanson., 2003), which would agree with our 
hypothesis derived from results in the previous chapter that proline synthesis acts to reduce 




4.3.8 Treatment alters glutamine metabolism in MB cells   
 
Many studies have shown that treatment induces alterations in the phenotype of the 
tumour, as well as its environment (Barker et al., 2015). Changes in metabolism after 
exposure to cytotoxic agents may reveal important mechanisms involved in treatment 
resistance, but despite this, studies focused on this are lacking in human tumours. We show 
for the first time in MB cell lines that glutamine flux is rapidly altered after H2O2 treatment. 
Our results demonstrate that the MB cell lines have different glutamine-related 
metabolisms, where the DAOY and UW228.3 lines increase their direct glutamine flux into 
glutamate, as seen by increased m+5 glutamate. These findings further highlight the 
importance of glutamate in MB resistance to treatment, and suggest these cell lines 
increase glutamate-derived pathways as a response to oxidative stresses, in this case 
towards H2O2 treatment. H2O2 is known to have a short half-life in cells, where it is quickly 
detoxified. This short-lived effect of H2O2 may not be ideal to elicit responses in 
13C flux and 
may explain the small changed observed. We therefore recommend this experiment to be 
repeated with both cisplatin and irradiation treatment. However, despite interesting 
findings, further work will be required to pull apart the precise metabolic changes 
associated with treatment. A recent study analysed altered metabolism in human breast 
cancer cell lines after BPTES treatment. Their work highlighted alterations in numerous 
metabolic pathways and offers vital metabolic information regarding treatment resistance 
mechanisms (Gowda et al., 2018). More studies like ours and those performed by Gowda et 




4.3.9 Hypoxia in MB. 
 
Hypoxic microenvironments commonly occur in tumours. The stabilisation of HIF 
transcription factors (HIF-1α and HIF-2α) can enable cell survival and propagation of the 
tumour, through increasing; blood vessel formation, metastasis, and resistance to 
treatment. The presence of hypoxia in MB tumours has not been shown. However, the 
impact of hypoxia – particularly the role of HIF-1α – has been demonstrated (Pistollato et 
al., 2010). Our results reveal hypoxic niches within MB patient tumours, suggesting for the 
first time that these tumours exhibit areas of low oxygen tension. Furthermore, MB cell lines 
showed an increase in the proportion of m+5 citrate when incubated in 1% O2 (hypoxia), 
consistent with the reductive carboxylation of glutamine-derived αKG as previously 
reported in hypoxic cells to support de novo lipogenesis (Metallo et al. 2011; Wise et al. 
2011). We also show that hypoxia may be able to permit resistance to treatment in MB, 
which aligns with recent investigations, where it was revealed that Hypoxia increases 
chemoresistance in DAOY cells via HIF1α-mediated downregulation of the CYP2B6, CYP3A4 
and CYP3A5 enzymes (Valencia-Cervantes et al., 2019).  Although we did not find the exact 
mechanism in our cell line models, we suggest the reducing environment accompanying 
hypoxia may play a part and may also reduce the effectiveness of SSZ treatment, which we 
previously highlighted as a potential therapy in normoxia. The lack of efficacy observed with 
SSZ treatment in hypoxia suggests that applying this type of therapy in clinical practice may 
prove a challenge, depending on the degree of hypoxia in a given tumour. Alternatively, if 
normoxia is necessary for SSZ treatment efficacy, pre-treatment with vasculature 
normalising agents such as bevacizumab may be beneficial, where these types of therapies 
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have already been used extensively in the treatment of cancers (Burger et al., 2011; Gilbert 
et al., 2014).  
4.3.10 Summary 
 
In this chapter, we investigated the mechanisms in which glutamine modulates therapeutic 
resistance in MB cell lines. Our results show that glutamine deprivation on its own leads to 
cellular death, but also increases cell line sensitisation to cytotoxic agents. We further 
showed that these mechanisms for resistance were directed through glutamate, the 
inhibition of which also resulted in a potentiation of treatments. Our results are consistent 
with the idea that disrupting glutamine metabolism, and several of its downstream 













































Research presented highlights the pathways influencing glutamine, and resulting glutamate 
metabolism and their importance in MB biology. Through the analysis of online mRNA 
expression data sets and biological in vitro investigations, we now better understand these 
pathways in MB and have exposed possible approaches to improve current therapies. 
5.1 The implication of glutamine/glutamate metabolic pathways in MB prognosis 
 
We defined a list of genes representative of different features of glutamine and glutamate 
metabolism and considered their role in MB biology, as well as patient survival. Genes 
representing glutamine catabolism, glutamate transport and receptor activity, proline 
biosynthesis, glutathione biosynthesis, and GABA biosynthesis and GABAergic activity, were 
either increased in higher grade MB subgroups (SHH, G3 or G4 compared to WNT) or were 
associated with poor prognosis.  
The data presented investigate the expression of metabolic genes and their clinical 
consequences in MB patients. We noted that in all cases, expression of the glutamate 
uptake transporters EAAT1 and EAAT2-4 were reduced, while the neutral amino acid 
transporter SLC1A5, responsible for the transport of glutamine into tumour cells, was 
significantly increased. Furthermore, the expression of these transporters proved to be 
prognostic, with low EAAT1 and high SLC1A5 being predictive of a worse overall survival in 
MB patients. Our data suggests that MB tumours prioritise glutamine uptake and 
subsequently utilise de novo glutamate synthesis rather than exogenous uptake. 
We also investigated genes involved in glutamine catabolism (GLS1, GLS2 and GLUD1) and 
anabolism (GLUL) in MB tumours.  GLS1 expression was highest in the SHH-MB subgroup 
when compared to the other three conventional groups, although when compared to 
normal cerebellum (CB) no expression differences were observed. Furthermore, we showed 
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changes in GLS1 expression between MB and CB, although no significance was observed for 
GLS1 expression and patient survival in the Newcastle cohort. Despite this, using another 
online expression database (GEO: GDS4471) we show high expressing GLS1 patients have a 
worse overall survival than low GLS1 expressing patients. Our proteomic data further reveal 
an importance of GLS1 expression in predicting survival. We show no expression changes in 
GLS2 in MB tumours when compared to normal cerebellum.  
Our results revealed a significant alteration in GLUD1, with decreased expression found in 
the SHH, Grp3 and Grp MB subgroups, which are have a more aggressive phenotype than 
the WNT group. We also observed decreased expression in MB tumours compared to CB, 
which interestingly held up as a prognostic indicator in patients, with low expressing 
patients having a significantly poorer overall survival (OS) compared to their higher GLUD1-
expressing counterparts.  
5.2 Biological characterisation of glutamine/glutamate metabolic pathways in MB cell lines 
 
After establishing that genes involved in glutamine/glutamate metabolism could play a role 
in the pathogenesis of MB, we investigated this further by several biological means. 
Similarly to our observations regarding the glutamine uptake transporter SLC1A5 in MB 
survival, we found that MB cell lines are glutamine ‘addicted’. Not only is glutamine 
required for cell growth, but it is also important in cell line resistance to cytotoxic 
treatments, which we have shown to be largely driven through glutamate.  
5.3 The role of GLS1 in MB  
 
Many studies have focused on glutamine metabolism in cancer and although we have also 
explored this role, we primarily focused our attentions to the role of glutamate. Our data 
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highlight the importance of GLS1 in the deamination of glutamine to glutamate under basal 
and stressed conditions. We show through the use of GLS1 knockdown experiments that 
GLS1 is required for the growth of MB cell lines and that this isoform is solely responsible for 
glutaminolysis. We showed, for the first time, the relative expressions of the GLS1 splice 
variants, KGA and GAC, where GAC expression is increased compared to KGA. We also 
elucidate the localisation differences between the GLS1 variants and observed increased 
KGA localising in the cytosol, while GAC typically localises to the mitochondria. We further 
show, through the use of 13C labelled glutamine that GAC is more responsible for label 
incorporation into several metabolites compared to KGA, indicative of preferential GAC-
derived TCA cycle metabolism. We suggest that mitochondrial located, GAC may be more 
important in TCA anaplerosis, while KGA may be responsible for (but not restricted to) 
controlling cytosolic concentrations of glutamate and its subsequent reactions. 
5.4 Clinical implications 
 
We reveal the role of GLS1 on the resistance against cytotoxic treatments. Knockdown of 
GLS1 resulted in increased potentiation of hydrogen peroxide, cisplatin and irradiation, 
suggesting that blocking the conversion of glutamine to glutamate may increase the efficacy 
of chemotherapy in MB tumours. We built on this data further through GLS1 compound 
inhibition with BPTES, which although introduces potential complications through off target 
effects, provides an opportunity for translation to the clinic. Our results highlight the 
beneficial use of clinically available GLS1 inhibitors in the treatment of MB cell lines, which 
may be used to improve treatment options in MB patients. 
Our results suggest that MB do not actively use GLS2 for glutaminolysis. However, we reveal 
a role of GLS2 in the protection against treatment, despite GLS2 having little role under 
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basal conditions. GLS2 expression is increased after treatment, suggesting a role of this 
enzyme in conditions of stress. We therefore highlighted the importance of GLS2 expression 
in MB treatment resistance, justifying further research with an aim to progress into the 
clinic.  
Independently of GLS, we found that inhibiting the glutamate-cystine anti-porter (SLC7A11) 
with SSZ renders MB cell lines sensitive to hydrogen peroxide treatment. The MB cell lines 
used demonstrated a degree of heterogeneity with respect to glutaminase expression and 
inhibition sensitivity, but with respect to SCL7A11 inhibition, all three cell lines responded 
similarly. Unsurprisingly, we confirmed the importance of GSH in the resistance against 
treatment, where SZZ significantly reduced intracellular concentrations of cystine which 
subsequently decreased the GSH:GSSG  ratio in the MB cell lines.  We demonstrated the 
specificity of SZZ treatment by displaying how this effect could be abolished by the addition 
of the reducing agent, 2-mercaptoethanol (2-ME), which facilitates the uptake of cystine 
independently of the xCT transporter by reducing cystine to cysteine, which allows its 
uptake through an alternative transporter. Our results reveal an alternative target of 
glutamate metabolism for MB tumours, independent of glutaminase, which could 
potentially be used clinically. Importantly, our data may highlight GSH as a converging 
molecule in MB. 
5.5 Regulation of glutamate concentrations in MB. 
 
We observed increased expression of the biosynthetic genes (ALDH18A1, PYCR1 and 
PYCR2), suggestive of heightened proline biosynthesis. We also found decreased PRODH 
expression, which is required for the breakdown of proline, and thus strengthening the 
notion that MB tumours favour proline anabolism. We suggest that this amplified proline 
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biosynthesis from glutamate may offer a way in which to remove excess mitochondrial 
glutamate. 
Furthermore, we show that the addition of exogenous proline decreases growth in all three 
cell lines in a concentration dependent manner. We demonstrated that the addition of 
exogenous proline reduces PYCR activity, resulting in decreased proline biosynthesis in our 
cell lines, which has been previously been shown to be the case in melanoma (de Ingeniis et 
al., 2012). As a large source of proline in our cell lines, we would expect glutamate 
concentrations to increase as a result of reduced proline biosynthesis. We propose this 
might affect the finely controlled concentrations of glutamate, which we believe to be an 
important mechanism in MB, and may be the cause of reduced MB cell growth.  
5.6. Future studies 
 
There are several areas within this work which require addressing in future experiments. I 
have been successfully awarded the Midlands neuroscience teaching and research fund, 
which I aim to use to address these. 
Although we show differential localisation of the GAC and KGA variants of GLS, we were 
unable to reveal the significance of this. Future studies will investigate the mitochondrial or 
cytosolic specific reactions that may be preferentially catalysed by one of the two variants. I 
will continue to utilise siRNA mediated knock down of GCA and KGA and assess by LC-MS 
the metabolic changes accompanied by reduced expression. Targeting GLS1 has brought 
with it complications due to the importance of this enzyme in normal tissue. However, the 
further understanding of the GLS1 variants could lead to more specific inhibitors in which to 




Furthermore, we have highlighted the potential importance of proline in MB, yet, did not 
expand upon this in our treatment chapter. I intend on inhibiting proline biosynthetic 
enzymes, by means of siRNA and/or compound inhibition in order to investigate the 
importance of these enzymes in MB biology. In particular, I would like to determine the 
changes in glutamate concentrations within the MB cell lines to further understand the 
importance of regulated glutamate concentrations. 
 
5.7 Conclusions  
 
Glutamine and glutamate are important metabolites, capable of impacting a diverse range 
of processes. Their clinical importance in MB is poorly understood, where the underlying 
metabolic pathways are relatively unexplored. Using gene expression, we found that 
glutamine/glutamate-associated pathways can predict survival. Additionally, we reveal that 
MB cells have heightened glutamine uptake, of which they subsequently rely of GLS1 for the 
biosynthesis of glutamate. We have highlighted several potential importance’s of glutamate 
in MB, which significantly supports previous in vivo data showing glutamate as a prognostic 
marker (Wilson et al., 2014). In addition to supporting these data, we show the majority of 
glutamate detected in MB tumours is likely to be extracellular (micro environmental), which 
may have important clinical consequences. Importantly, we showed that manipulation of 
metabolic enzymes can improve (at least in vitro) the current therapies for MB treatment 
suggesting that glutamate metabolism represent a therapeutic target to supplement 
existing treatment regimens. Through analysis of clinical data sets and in vitro 
investigations, we have revealed several fundamental areas of glutamate metabolism in MB 
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Supplementary figure 1. Expression of glutamate-related genes was 
associated with survival in MB tumours.  A) Representative Kaplan-Meier 
survival curves of the online NCBI Geo repository (accession number: 
GDS4471). This Expression profiling array, included 76 samples, each belonging 
to the separate MB subgroups; WNT (n=8), SHH (n=11), G3 (n=16) and G4 
(n=39). High and low expression was determined by the median expression 
value for each gene. Log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon 
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Supplementary figure 2. RNAi of GLS1 and GLS2 reduces RNA and protein levels. 
A) Western blot showing reduced protein upon knockdown with siGLS1 or siGLS2 
after 48h. B) qPCR data showing reduced RNA levels of GLS1 or GLS2 after 24, 48 



















































Supplementary figure 3. Histologic illustration of collagen in 
normal cerebellum (CB) and MB. The tumour shows increased 









































































































































































































Figure 4.2.6. Pre-treatment with C968 leads to increased cytotoxicity of Cisplatin treatment in MB cell 
lines. A) Cell death was examined using a flow cytometry AnnexinV/PI assay to determine the effectiveness 
of C968 on ONS-76, DAOY and UW228.3 cell lines. Cells treated with DMSO, C968, Cisplatin or a 
combination of C968 and cisplatin. C968 pre-treatment 24 hours prior to cisplatin treatment does not affect 
cell viability. Data presented as mean ±SEM representative of three separate experiments. Significance was 
determined by performing a one-way ANOVA with Tukey post-hoc test in Graphpad; *p<0.05, **p<0.01, 
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GEO: GSE42658 GEO: GDS4471 
Supplementary figure 5. Expression of glutathione-related genes was 
associated with survival in MB tumours.  A) Representative Kaplan-Meier 
survival curves of the online NCBI Geo repository (accession number: 
GDS4471). This Expression profiling array, included 76 samples, each 
belonging to the separate MB subgroups; WNT (n=8), SHH (n=11), G3 (n=16) 
and G4 (n=39). High and low expression was determined by the median 
expression value for each gene Log-rank (Mantel-Cox) and Gehan-Breslow-





























































Supplementary figure 6. CAIX staining reveals hypoxic regions in MB 
tumours. CAIX protein expression is increased in MB tumours compared 























































Supplementary figure 6. CAIX staining reveals hypoxic regions in MB 
tumours, continued. CAIX protein expression is increased in MB tumours 
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